<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK1127" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK1127/" /><meta name="ncbi_pagename" content="CLCN7-Related Osteopetrosis - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>CLCN7-Related Osteopetrosis - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="CLCN7-Related Osteopetrosis" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2016/06/09" /><meta name="citation_author" content="Cristina Sobacchi" /><meta name="citation_author" content="Anna Villa" /><meta name="citation_author" content="Ansgar Schulz" /><meta name="citation_author" content="Uwe Kornak" /><meta name="citation_pmid" content="20301306" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK1127/" /><meta name="citation_keywords" content="Autosomal Dominant Osteopetrosis Type II (ADOII)" /><meta name="citation_keywords" content="Infantile Malignant CLCN7-Related Autosomal Recessive Osteopetrosis (ARO)" /><meta name="citation_keywords" content="Intermediate Autosomal Osteopetrosis (IAO)" /><meta name="citation_keywords" content="H(+)/Cl(-) exchange transporter 7" /><meta name="citation_keywords" content="CLCN7" /><meta name="citation_keywords" content="CLCN7-Related Osteopetrosis" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="CLCN7-Related Osteopetrosis" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Cristina Sobacchi" /><meta name="DC.Contributor" content="Anna Villa" /><meta name="DC.Contributor" content="Ansgar Schulz" /><meta name="DC.Contributor" content="Uwe Kornak" /><meta name="DC.Date" content="2016/06/09" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK1127/" /><meta name="description" content="The spectrum of CLCN7-related osteopetrosis includes infantile malignant CLCN7-related recessive osteopetrosis (ARO), intermediate autosomal osteopetrosis (IAO), and autosomal dominant osteopetrosis type II (ADOII, Albers-Schönberg disease)." /><meta name="og:title" content="CLCN7-Related Osteopetrosis" /><meta name="og:type" content="book" /><meta name="og:description" content="The spectrum of CLCN7-related osteopetrosis includes infantile malignant CLCN7-related recessive osteopetrosis (ARO), intermediate autosomal osteopetrosis (IAO), and autosomal dominant osteopetrosis type II (ADOII, Albers-Schönberg disease)." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK1127/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/clcn7/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK1127/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8A8CC6E040B4A1000000000314011D.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK1127_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK1127_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/cc2-leuk/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/clpb-def/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK1127_"><span class="title" itemprop="name"><i>CLCN7</i>-Related Osteopetrosis</span></h1><p class="contrib-group"><span itemprop="author">Cristina Sobacchi</span>, MS, <span itemprop="author">Anna Villa</span>, MD, PhD, <span itemprop="author">Ansgar Schulz</span>, MD, and <span itemprop="author">Uwe Kornak</span>, MD, PhD.</p><a data-jig="ncbitoggler" href="#__NBK1127_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK1127_ai__"><div class="contrib half_rhythm"><span itemprop="author">Cristina Sobacchi</span>, MS<div class="affiliation small">CNR-IRGB, Milan Unit<br />Humanitas Clinical and Research Center<br />Rozzano, Italy<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ti.hcraesersatinamuh@ihccabos.anitsirc" class="oemail">ti.hcraesersatinamuh@ihccabos.anitsirc</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Anna Villa</span>, MD, PhD<div class="affiliation small">CNR-IRGB, Milan Unit<br />Humanitas Clinical and Research Center<br />Rozzano, Italy<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ti.hcraesersatinamuh@alliv.anna" class="oemail">ti.hcraesersatinamuh@alliv.anna</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Ansgar Schulz</span>, MD<div class="affiliation small">Universit&#x000e4;tsklinik f&#x000fc;r Kinder- und Jugendmedizin<br />Ulm, Germany<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ed.mlu-kinilkinu@zluhcs.ragsna" class="oemail">ed.mlu-kinilkinu@zluhcs.ragsna</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Uwe Kornak</span>, MD, PhD<div class="affiliation small">Institut f&#x000fc;r Medizinische Genetik und Humangenetik<br />Charit&#x000e9; Universit&#x000e4;tsmedizin<br />Berlin, Germany<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ed.etirahc@kanrok.ewu" class="oemail">ed.etirahc@kanrok.ewu</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">February 12, 2007</span>; Last Update: <span itemprop="dateModified">June 9, 2016</span>.</p><p><em>Estimated reading time: 29 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="clcn7.Summary" itemprop="description"><h2 id="_clcn7_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p>The spectrum of <i>CLCN7</i>-related osteopetrosis includes infantile malignant <i>CLCN7</i>-related recessive osteopetrosis (ARO), intermediate <a class="def" href="/books/n/gene/glossary/def-item/autosomal/">autosomal</a> osteopetrosis (IAO), and <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> osteopetrosis type II (ADOII, Albers-Sch&#x000f6;nberg disease).</p><ul><li class="half_rhythm"><div>Onset of ARO is in infancy. Findings may include: fractures; poor growth; sclerosis of the skull base (with or without choanal stenosis or hydrocephalus) resulting in optic nerve compression, facial palsy, and hearing loss; absence of the bone marrow cavity resulting in severe anemia and thrombocytopenia; dental abnormalities, odontomas, and risk for mandibular osteomyelitis; and hypocalcemia with tetanic seizures and secondary hyperparathyroidism. Without treatment maximal life span in ARO is ten years.</div></li><li class="half_rhythm"><div>Onset of IAO is in childhood. Findings may include fractures after minor trauma, characteristic skeletal radiographic changes found incidentally, mild anemia, and occasional visual impairment secondary to optic nerve compression. Life expectancy in IAO is usually normal.</div></li><li class="half_rhythm"><div>Onset of ADOII is usually late childhood or adolescence. Findings may include: fractures (in any long bone and/or the posterior arch of a vertebra), scoliosis, hip osteoarthritis, and osteomyelitis of the mandible or septic osteitis or osteoarthritis elsewhere. Cranial nerve compression is rare.</div></li></ul></div><div><h4 class="inline">Diagnosis/testing.</h4><p><i>CLCN7</i>-related osteopetrosis is suspected with identification of radiographic changes that are pathognomonic in ARO (generalized osteosclerosis, club-shaped long bones, osteosclerosis of the skull base, bone-within-bone appearance) and characteristic in ADOII (osteosclerosis of the spine ["sandwich vertebra" appearance], bone-within-bone appearance [mainly iliac wings], Erlenmeyer-shaped femoral metaphysis, mild osteosclerosis of the skull base, transverse bands of osteosclerosis in long bones). Identification of pathogenic variants in <i>CLCN7</i> establishes the diagnosis.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i></p><ul><li class="half_rhythm"><div>ARO. Calcium supplementation for hypocalcemic convulsions; management of calcium homeostasis per individual needs; erythrocyte or platelet transfusions as needed; antibiotics for leukocytopenia; immunoglobulins for hypogammaglobulinemia; surgical decompression of the optic nerve; treatment of fractures by an experienced orthopedist; dental care with attention to tooth eruption, ankylosis, abscesses, cysts, and fistulas.</div></li><li class="half_rhythm"><div>ADOII. Orthopedic treatment for fractures and arthritis with attention to potential post-surgical complications (delayed union or non-union of fractures, infection); fractures near joints may require total joint arthroplasty.</div></li></ul><p><i>Prevention of primary manifestations:</i> ARO. Hematopoietic stem cell transplantation (HSCT) can be curative; however, cranial nerve dysfunction is usually irreversible, and progressive neurologic sequelae occur in children with the neuronopathic form even after successful HSCT.</p><p><i>Prevention of secondary complications:</i></p><ul><li class="half_rhythm"><div>ARO. Restricted intake of calcium and vitamin D just before, during, and following HSCT to prevent hypercalcemia.</div></li><li class="half_rhythm"><div>ADOII. Good routine dental care and oral hygiene to help prevent osteomyelitis of the mandible.</div></li></ul><p><i>Surveillance:</i> ARO. Complete blood count and ophthalmologic examination at least once a year; follow up per the transplantation center following HSCT.</p><p><i>Agents/circumstances to avoid:</i> ADOII. Activities with high fracture risk.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>ARO is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner; ADOII is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner; about 40% of IAO is inherited in an autosomal recessive manner and about 60% in an autosomal dominant manner.</p><ul><li class="half_rhythm"><div><b>Autosomal recessive inheritance.</b> At conception, each sib of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual has a 25% chance of being affected, a 50% chance of being an asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and a 25% chance of being unaffected and not a carrier. In general, individuals with ARO only reproduce if successfully treated by HSCT.</div></li><li class="half_rhythm"><div><b>Autosomal dominant inheritance.</b> Most individuals diagnosed with <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> <i>CLCN7</i>-related osteopetrosis have an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> parent. The proportion of cases caused by <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> pathogenic variants is unknown. Each child of an individual with autosomal dominant <i>CLCN7</i>-related osteopetrosis has a 50% chance of inheriting the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</div></li></ul><p>Prenatal diagnosis for pregnancies at increased risk for ADOII and ARO is possible if the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>(s) have been identified in the family.</p></div></div><div id="clcn7.GeneReview_Scope"><h2 id="_clcn7_GeneReview_Scope_"><i>GeneReview</i> Scope</h2><div id="clcn7.Td" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1127/table/clcn7.Td/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__clcn7.Td_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_clcn7.Td_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>CLCN7</i>-Related Osteopetrosis: Included Phenotypes&#x000a0;<sup>1</sup></th></tr></thead><tbody><tr><td headers="hd_h_clcn7.Td_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Infantile malignant <i>CLCN7</i>-related <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> osteopetrosis (ARO)</div></li><li class="half_rhythm"><div>Intermediate <a class="def" href="/books/n/gene/glossary/def-item/autosomal/">autosomal</a> osteopetrosis (IAO)</div></li><li class="half_rhythm"><div>Autosomal dominant osteopetrosis type II (ADOII)</div></li></ul>
</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="clcn7.TF.d.1"><p class="no_margin">For other genetic causes of these phenotypes see <a href="#clcn7.Differential_Diagnosis">Differential Diagnosis</a>.</p></div></dd></dl></div></div></div></div><div id="clcn7.Diagnosis"><h2 id="_clcn7_Diagnosis_">Diagnosis</h2><p>The spectrum of <i>CLCN7</i>-related osteopetrosis includes:</p><ul><li class="half_rhythm"><div>Infantile malignant <i>CLCN7</i>-related <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> osteopetrosis (ARO);</div></li><li class="half_rhythm"><div>Intermediate <a class="def" href="/books/n/gene/glossary/def-item/autosomal/">autosomal</a> osteopetrosis (IAO);</div></li><li class="half_rhythm"><div>Autosomal dominant osteopetrosis type II (ADOII, Albers-Sch&#x000f6;nberg disease).</div></li></ul><div id="clcn7.Suggestive_Findings"><h3>Suggestive Findings</h3><p>A <i>CLCN7</i>-related osteopetrosis <b>should be suspected</b> in individuals with osteosclerosis noted on radiographs, which may be accompanied by hypocalcemia and resulting convulsions, anemia, thrombocytopenia, visual impairment, and/or CNS involvement (see <a class="figpopup" href="/books/NBK1127/table/clcn7.T.diagnostic_features_of_the_subty/?report=objectonly" target="object" rid-figpopup="figclcn7Tdiagnosticfeaturesofthesubty" rid-ob="figobclcn7Tdiagnosticfeaturesofthesubty">Table 1</a>).</p><div id="clcn7.T.diagnostic_features_of_the_subty" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Diagnostic Features of the Subtypes of <i>CLCN7</i>-Related Osteopetrosis</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1127/table/clcn7.T.diagnostic_features_of_the_subty/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__clcn7.T.diagnostic_features_of_the_subty_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_clcn7.T.diagnostic_features_of_the_subty_1_1_1_1" rowspan="2" scope="col" colspan="1" headers="hd_h_clcn7.T.diagnostic_features_of_the_subty_1_1_1_1" style="text-align:left;vertical-align:middle;">Finding</th><th id="hd_h_clcn7.T.diagnostic_features_of_the_subty_1_1_1_2" colspan="3" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Subtype of <i>CLCN7</i>-Related Osteopetrosis</th></tr><tr><th headers="hd_h_clcn7.T.diagnostic_features_of_the_subty_1_1_1_2" id="hd_h_clcn7.T.diagnostic_features_of_the_subty_1_1_2_1" colspan="1" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">ARO</th><th headers="hd_h_clcn7.T.diagnostic_features_of_the_subty_1_1_1_2" id="hd_h_clcn7.T.diagnostic_features_of_the_subty_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">IAO</th><th headers="hd_h_clcn7.T.diagnostic_features_of_the_subty_1_1_1_2" id="hd_h_clcn7.T.diagnostic_features_of_the_subty_1_1_2_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">ADOII</th></tr></thead><tbody><tr><td headers="hd_h_clcn7.T.diagnostic_features_of_the_subty_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Radiographic changes</td><td headers="hd_h_clcn7.T.diagnostic_features_of_the_subty_1_1_1_2 hd_h_clcn7.T.diagnostic_features_of_the_subty_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Pathognomonic&#x000a0;<sup>1</sup></td><td headers="hd_h_clcn7.T.diagnostic_features_of_the_subty_1_1_1_2 hd_h_clcn7.T.diagnostic_features_of_the_subty_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Characteristic&#x000a0;<sup>2</sup></td><td headers="hd_h_clcn7.T.diagnostic_features_of_the_subty_1_1_1_2 hd_h_clcn7.T.diagnostic_features_of_the_subty_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Characteristic&#x000a0;<sup>3</sup></td></tr><tr><td headers="hd_h_clcn7.T.diagnostic_features_of_the_subty_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Hypocalcemia</td><td headers="hd_h_clcn7.T.diagnostic_features_of_the_subty_1_1_1_2 hd_h_clcn7.T.diagnostic_features_of_the_subty_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Severe to absent</td><td headers="hd_h_clcn7.T.diagnostic_features_of_the_subty_1_1_1_2 hd_h_clcn7.T.diagnostic_features_of_the_subty_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Absent</td><td headers="hd_h_clcn7.T.diagnostic_features_of_the_subty_1_1_1_2 hd_h_clcn7.T.diagnostic_features_of_the_subty_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Absent</td></tr><tr><td headers="hd_h_clcn7.T.diagnostic_features_of_the_subty_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Anemia</td><td headers="hd_h_clcn7.T.diagnostic_features_of_the_subty_1_1_1_2 hd_h_clcn7.T.diagnostic_features_of_the_subty_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Severe to moderate</td><td headers="hd_h_clcn7.T.diagnostic_features_of_the_subty_1_1_1_2 hd_h_clcn7.T.diagnostic_features_of_the_subty_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Mild to absent</td><td headers="hd_h_clcn7.T.diagnostic_features_of_the_subty_1_1_1_2 hd_h_clcn7.T.diagnostic_features_of_the_subty_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Absent</td></tr><tr><td headers="hd_h_clcn7.T.diagnostic_features_of_the_subty_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Thrombocytopenia</td><td headers="hd_h_clcn7.T.diagnostic_features_of_the_subty_1_1_1_2 hd_h_clcn7.T.diagnostic_features_of_the_subty_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Severe to absent</td><td headers="hd_h_clcn7.T.diagnostic_features_of_the_subty_1_1_1_2 hd_h_clcn7.T.diagnostic_features_of_the_subty_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Absent</td><td headers="hd_h_clcn7.T.diagnostic_features_of_the_subty_1_1_1_2 hd_h_clcn7.T.diagnostic_features_of_the_subty_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Absent</td></tr><tr><td headers="hd_h_clcn7.T.diagnostic_features_of_the_subty_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Visual impairment</td><td headers="hd_h_clcn7.T.diagnostic_features_of_the_subty_1_1_1_2 hd_h_clcn7.T.diagnostic_features_of_the_subty_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Frequent</td><td headers="hd_h_clcn7.T.diagnostic_features_of_the_subty_1_1_1_2 hd_h_clcn7.T.diagnostic_features_of_the_subty_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Rare</td><td headers="hd_h_clcn7.T.diagnostic_features_of_the_subty_1_1_1_2 hd_h_clcn7.T.diagnostic_features_of_the_subty_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Very rare</td></tr><tr><td headers="hd_h_clcn7.T.diagnostic_features_of_the_subty_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">CNS involvement</td><td headers="hd_h_clcn7.T.diagnostic_features_of_the_subty_1_1_1_2 hd_h_clcn7.T.diagnostic_features_of_the_subty_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Severe to absent</td><td headers="hd_h_clcn7.T.diagnostic_features_of_the_subty_1_1_1_2 hd_h_clcn7.T.diagnostic_features_of_the_subty_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Absent</td><td headers="hd_h_clcn7.T.diagnostic_features_of_the_subty_1_1_1_2 hd_h_clcn7.T.diagnostic_features_of_the_subty_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Absent</td></tr><tr><td headers="hd_h_clcn7.T.diagnostic_features_of_the_subty_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Age of onset of symptoms</td><td headers="hd_h_clcn7.T.diagnostic_features_of_the_subty_1_1_1_2 hd_h_clcn7.T.diagnostic_features_of_the_subty_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Birth</td><td headers="hd_h_clcn7.T.diagnostic_features_of_the_subty_1_1_1_2 hd_h_clcn7.T.diagnostic_features_of_the_subty_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">First 2 years</td><td headers="hd_h_clcn7.T.diagnostic_features_of_the_subty_1_1_1_2 hd_h_clcn7.T.diagnostic_features_of_the_subty_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">First 10 years</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">ADOII = <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> osteopetrosis type II; ARO = infantile malignant autosomal <i>CLCN7</i>-related <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> osteopetrosis; IAO = intermediate autosomal osteopetrosis</p></div></dd><dt>1. </dt><dd><div id="clcn7.TF.1.1"><p class="no_margin">Generalized osteosclerosis, club-shaped long bones, sclerosis of the skull base, bone-within-bone appearance</p></div></dd><dt>2. </dt><dd><div id="clcn7.TF.1.2"><p class="no_margin">Findings similar to ARO, already present in early childhood, but less severe</p></div></dd><dt>3. </dt><dd><div id="clcn7.TF.1.3"><p class="no_margin">Findings include: <br /> &#x02022;&#x000a0;Osteosclerosis of the spine ("sandwich vertebrae") <br /> &#x02022;&#x000a0;Bone within bone appearance, mainly in iliac wings <br /> &#x02022;&#x000a0;Erlenmeyer-shaped femoral metaphysis <br /> &#x02022;&#x000a0;Mild osteosclerosis of the skull base <br /> &#x02022;&#x000a0;Transverse bands of osteosclerosis in long bones</p></div></dd></dl></div></div></div></div><div id="clcn7.Establishing_the_Diagnosis"><h3>Establishing the Diagnosis</h3><p>The diagnosis of a <i>CLCN7</i>-related osteopetrosis <b>is established</b> in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> through the identification of <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants or a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>CLCN7</i> by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> (see <a class="figpopup" href="/books/NBK1127/table/clcn7.T.molecular_genetic_testing_used_i/?report=objectonly" target="object" rid-figpopup="figclcn7Tmoleculargenetictestingusedi" rid-ob="figobclcn7Tmoleculargenetictestingusedi">Table 3</a>).</p><p>Molecular testing approaches can include <b>single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing</b> and use of a <b><a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b>:</p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing.</b> Sequence analysis of <i>CLCN7</i> is performed first followed by gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> if only one or no <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is found.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>A <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b> that includes <i>CLCN7</i> and other genes of interest (see <a href="#clcn7.Differential_Diagnosis">Differential Diagnosis</a>) may also be considered. Note: (1) The genes included in the panel and the diagnostic <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of the testing used for each <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this <i>GeneReview</i>; thus, clinicians need to determine which multigene panel is most likely to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a> and pathogenic variants in genes that do not explain the underlying <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused <a class="def" href="/books/n/gene/glossary/def-item/exome/">exome</a> analysis that includes genes specified by the clinician. (4) Methods used in a panel may include <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>, and/or other non-sequencing-based tests.</div><div class="half_rhythm">For an introduction to multigene panels click <a href="/books/n/gene/app5/#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/#app5.Multigene_Panels_FAQs">here</a>.</div></li></ul><p>The proportion of all osteopetrosis caused by pathogenic variants in <i>CLCN7</i> is summarized in <a class="figpopup" href="/books/NBK1127/table/clcn7.T.proportion_of_osteopetrosis_phen/?report=objectonly" target="object" rid-figpopup="figclcn7Tproportionofosteopetrosisphen" rid-ob="figobclcn7Tproportionofosteopetrosisphen">Table 2</a>.</p><div id="clcn7.T.proportion_of_osteopetrosis_phen" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Proportion of Osteopetrosis Phenotype Caused by Pathogenic Variants in <i>CLCN7</i></p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1127/table/clcn7.T.proportion_of_osteopetrosis_phen/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__clcn7.T.proportion_of_osteopetrosis_phen_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_clcn7.T.proportion_of_osteopetrosis_phen_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Osteopetrosis Phenotype</th><th id="hd_h_clcn7.T.proportion_of_osteopetrosis_phen_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"># of <i>CLCN7</i> Pathogenic Variants</th><th id="hd_h_clcn7.T.proportion_of_osteopetrosis_phen_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">% of Osteopetrosis Caused by Pathogenic Variants in <i>CLCN7</i></th></tr></thead><tbody><tr><td headers="hd_h_clcn7.T.proportion_of_osteopetrosis_phen_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Infantile malignant <i>CLCN7</i>-related <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> osteopetrosis (ARO)</td><td headers="hd_h_clcn7.T.proportion_of_osteopetrosis_phen_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">2</td><td headers="hd_h_clcn7.T.proportion_of_osteopetrosis_phen_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">13%</td></tr><tr><td headers="hd_h_clcn7.T.proportion_of_osteopetrosis_phen_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;">Intermediate <a class="def" href="/books/n/gene/glossary/def-item/autosomal/">autosomal</a> osteopetrosis (IAO)</td><td headers="hd_h_clcn7.T.proportion_of_osteopetrosis_phen_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">2</td><td headers="hd_h_clcn7.T.proportion_of_osteopetrosis_phen_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">40%&#x000a0;<sup>1</sup></td></tr><tr><td headers="hd_h_clcn7.T.proportion_of_osteopetrosis_phen_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">1</td><td headers="hd_h_clcn7.T.proportion_of_osteopetrosis_phen_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">60%&#x000a0;<sup>1</sup></td></tr><tr><td headers="hd_h_clcn7.T.proportion_of_osteopetrosis_phen_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Autosomal dominant osteopetrosis type II (ADOII)</td><td headers="hd_h_clcn7.T.proportion_of_osteopetrosis_phen_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1</td><td headers="hd_h_clcn7.T.proportion_of_osteopetrosis_phen_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">75%&#x000a0;<sup>2</sup></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="clcn7.TF.2.1"><p class="no_margin"><a class="bk_pop" href="#clcn7.REF.camposxavier.2003.186">Campos-Xavier et al [2003]</a>, <a class="bk_pop" href="#clcn7.REF.frattini.2003.1740">Frattini et al [2003]</a>, <a class="bk_pop" href="#clcn7.REF.pangrazio.2010.e1071">Pangrazio et al [2010]</a></p></div></dd><dt>2. </dt><dd><div id="clcn7.TF.2.2"><p class="no_margin"><a class="bk_pop" href="#clcn7.REF.del_fattore.2006.315">Del Fattore et al [2006]</a> found <i>CLCN7</i> pathogenic variants in 78% of individuals with ADOII; <a class="bk_pop" href="#clcn7.REF.frattini.2003.1740">Frattini et al [2003]</a> found <i>CLCN7</i> pathogenic variants in 72% of individuals with ADOII. In other cohorts, rates may be higher [unpublished observations]. It remains possible that pathogenic variants in another <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> cause the ADOII <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> in a subset of cases.</p></div></dd></dl></div></div></div><div id="clcn7.T.molecular_genetic_testing_used_i" class="table"><h3><span class="label">Table 3. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in <i>CLCN7</i>-Related Osteopetrosis</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1127/table/clcn7.T.molecular_genetic_testing_used_i/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__clcn7.T.molecular_genetic_testing_used_i_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_clcn7.T.molecular_genetic_testing_used_i_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_clcn7.T.molecular_genetic_testing_used_i_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Method</th><th id="hd_h_clcn7.T.molecular_genetic_testing_used_i_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Proportion of Probands with a Pathogenic Variant&#x000a0;<sup>2</sup> Detectable by Method</th></tr></thead><tbody><tr><td headers="hd_h_clcn7.T.molecular_genetic_testing_used_i_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>CLCN7</i></td><td headers="hd_h_clcn7.T.molecular_genetic_testing_used_i_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>3</sup></td><td headers="hd_h_clcn7.T.molecular_genetic_testing_used_i_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~95%&#x000a0;<sup>4</sup></td></tr><tr><td headers="hd_h_clcn7.T.molecular_genetic_testing_used_i_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>&#x000a0;<sup>5</sup></td><td headers="hd_h_clcn7.T.molecular_genetic_testing_used_i_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown&#x000a0;<sup>6,&#x000a0;7</sup></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="clcn7.TF.3.1"><p class="no_margin">See <a href="/books/NBK1127/#clcn7.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="clcn7.TF.3.2"><p class="no_margin">See <a href="#clcn7.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>3. </dt><dd><div id="clcn7.TF.3.3"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and splice-site variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>4. </dt><dd><div id="clcn7.TF.3.4"><p class="no_margin">Virtually all pathogenic variants reported in the literature have been identified by sequencing of the <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>, the majority by classical <a class="def" href="/books/n/gene/glossary/def-item/sanger-sequencing/">Sanger sequencing</a>, more recently also by <a class="def" href="/books/n/gene/glossary/def-item/exome/">exome</a> or gene panel-based sequencing [Author, personal observation].</p></div></dd><dt>5. </dt><dd><div id="clcn7.TF.3.5"><p class="no_margin">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> detects intragenic deletions or duplications. Methods used may include <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted microarray designed to detect single-<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions or duplications.</p></div></dd><dt>6. </dt><dd><div id="clcn7.TF.3.6"><p class="no_margin">Example of <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> 101-kb <a class="def" href="/books/n/gene/glossary/def-item/contiguous-gene-deletion/">contiguous gene deletion</a> including exons 7-25 of <i>CLCN7</i> [<a class="bk_pop" href="#clcn7.REF.pangrazio.2012.250">Pangrazio et al 2012</a>]</p></div></dd><dt>7. </dt><dd><div id="clcn7.TF.3.7"><p class="no_margin">No data on detection rate of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> are available.</p></div></dd></dl></div></div></div></div></div><div id="clcn7.Clinical_Characteristics"><h2 id="_clcn7_Clinical_Characteristics_">Clinical Characteristics</h2><div id="clcn7.Clinical_Description"><h3>Clinical Description</h3><div id="clcn7.Infantile_Malignant_CLCN7Related_A"><h4>Infantile Malignant <i>CLCN7</i>-Related Autosomal Recessive Osteopetrosis (ARO)</h4><p>ARO is a systemic, life-threatening disorder. Without treatment, life span is approximately ten years (although rare exceptions of far longer survival have occurred). Possible clinical manifestations of ARO:</p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Fractures.</b> The near-complete absence of osteoclastic bone resorption caused by the loss of H(+)/Cl(-) exchange transporter 7 (also known as ClC-7) leads to osteosclerosis of the whole skeleton within the first few months after birth (<a class="figpopup" href="/books/NBK1127/figure/clcn7.F1/?report=objectonly" target="object" rid-figpopup="figclcn7F1" rid-ob="figobclcn7F1">Figure 1</a>). Because of defective microarchitecture, the bones become brittle, resulting in recurrent fractures (usually of the long bones).</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Reduced growth.</b> Resorption of cartilage and bone at the growth plate is a prerequisite for longitudinal growth; its absence results in variable growth retardation. In severely <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> children, body length at age 12 months is as much as 5 cm below the third centile.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Skull.</b> In some severely <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> children, macrocephaly and frontal bossing develop within the first year. This is not necessarily paralleled by sclerosis of the cranial vault. The sclerosis of the skull base often leads to choanal stenosis. Skull changes may also cause hydrocephalus.</div></li><li class="half_rhythm"><div class="half_rhythm">Neurologic complications</div><ul><li class="half_rhythm"><div>Visual impairment beginning shortly after birth is common. In most cases it is caused by optic nerve compression within the osteosclerotic skull base.</div></li><li class="half_rhythm"><div>A prominent and large anterior fontanelle is common and sometimes associated with hydrocephalus, possibly caused by obstruction of cerebral blood flow and cerebrospinal fluid (CSF) circulation as a result of hyperostosis.</div></li><li class="half_rhythm"><div>Facial palsy caused by facial nerve entrapment is an uncommon manifestation.</div></li><li class="half_rhythm"><div>Seizures can result from hypocalcemia.</div></li></ul></li><li class="half_rhythm"><div class="half_rhythm"><b>Neuronopathic form.</b> If seizures appear together with normal serum calcium concentration and developmental delay, a neuronopathic form must be considered. In these cases the neuronal <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> resembles neuronal ceroid-lipofuscinosis [<a class="bk_pop" href="#clcn7.REF.steward.2003.87">Steward 2003</a>]. In this subset of very severely <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> children, primary degeneration of the retina and CNS occurs. It is important to differentiate these rare primary neurologic manifestations of the neuronopathic form of ARO (which has a poor prognosis) from more common secondary lesions resulting from hyperostosis of the skull base. It is noteworthy that pathologic EEG changes with a characteristic pattern of very frequent multifocal spikes and sharp waves usually precede the clinical symptoms and brain MRI findings of neurodegeneration [A Schulz, unpublished results].</div><div class="half_rhythm">The basis of the neuronopathic form of ARO is as yet incompletely understood, but neurologic complications are more common and more severe in persons with <i>CLCN7</i> pathogenic variants than in those with <i>TCIRG1</i>-related ARO [<a class="bk_pop" href="#clcn7.REF.pangrazio.2010.e1071">Pangrazio et al 2010</a>; A Schulz, unpublished results], while all individuals with <i>OSTM1</i>-related ARO have CNS involvement. This is mirrored by neurodegeneration in <i>Clcn7</i>- and <i>Ostm1</i>-null mice [<a class="bk_pop" href="#clcn7.REF.kasper.2005.1079">Kasper et al 2005</a>, <a class="bk_pop" href="#clcn7.REF.lange.2006.220">Lange et al 2006</a>]. Ostm1 is a beta subunit of ClC-7 and is required for its transport activity [<a class="bk_pop" href="#clcn7.REF.leisle.2011.2140">Leisle et al 2011</a>].</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Otologic manifestations.</b> According to <a class="bk_pop" href="#clcn7.REF.dozier.2005.762">Dozier et al [2005]</a>, 78% of individuals with ARO showed variable hearing loss. Poor pneumatization of the mastoid bone and narrowing of the external auditory canal, eustachian tube, and internal auditory canal frequently lead to otitis media, conductive and sensorineural hearing loss, and facial nerve paralysis [<a class="bk_pop" href="#clcn7.REF.dozier.2005.762">Dozier et al 2005</a>].</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Dental.</b> Oral problems in ARO are delayed tooth eruption, hypodontia, malformed teeth, enamel hypoplasia, hypomineralization of enamel and dentin, the presence of odontomas, and severe mandibular osteomyelitis. Even if the primary dentition is impaired, the secondary dentition can be normal after successful stem cell transplantation [<a class="bk_pop" href="#clcn7.REF.j_levik.2002.537">J&#x000e4;levik et al 2002</a>, <a class="bk_pop" href="#clcn7.REF.helfrich.2005.115">Helfrich 2005</a>, <a class="bk_pop" href="#clcn7.REF.luzzi.2006.39">Luzzi et al 2006</a>].</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Hypocalcemia.</b> Hypocalcemia may result in tetanic seizures and secondary hyperparathyroidism.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Anemia and thrombocytopenia.</b> The absence of the bone marrow cavity leads to extramedullary hematopoiesis, hepatosplenomegaly, anemia, and thrombocytopenia. The bleeding associated with thrombocytopenia can be severe and life threatening, especially in the CNS.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Immune function.</b> Immune function may be impaired. Leukocytosis, present in the early stage of the disease, can become leukocytopenia. In conjunction with the frequently observed choanal stenosis, impaired immune function may lead to chronic rhinitis. Defective superoxide generation by granulocytes and monocytes has been reported in ARO [<a class="bk_pop" href="#clcn7.REF.wilson.2000.449">Wilson &#x00026; Vellodi 2000</a>].</div></li></ul><div class="iconblock whole_rhythm clearfix ten_col fig" id="figclcn7F1" co-legend-rid="figlgndclcn7F1"><a href="/books/NBK1127/figure/clcn7.F1/?report=objectonly" target="object" title="Figure 1. " class="img_link icnblk_img figpopup" rid-figpopup="figclcn7F1" rid-ob="figobclcn7F1"><img class="small-thumb" src="/books/NBK1127/bin/clcn7-Image001.gif" src-large="/books/NBK1127/bin/clcn7-Image001.jpg" alt="Figure 1. " /></a><div class="icnblk_cntnt" id="figlgndclcn7F1"><h4 id="clcn7.F1"><a href="/books/NBK1127/figure/clcn7.F1/?report=objectonly" target="object" rid-ob="figobclcn7F1">Figure 1. </a></h4><p class="float-caption no_bottom_margin">ARO x-rays </p></div></div></div><div id="clcn7.Intermediate_Autosomal_Osteopetros"><h4>Intermediate Autosomal Osteopetrosis (IAO)</h4><p>IAO is characterized by childhood onset with a milder course than ARO. Life expectancy is normal in most cases. Children may present with fractures after minor trauma or characteristic changes on x-rays obtained for other clinical indications. Hematologic signs are milder than those in ARO and are usually restricted to anemia. Although CNS involvement is usually absent, visual impairment secondary to optic nerve encroachment can occur [<a class="bk_pop" href="#clcn7.REF.camposxavier.2003.186">Campos-Xavier et al 2003</a>, <a class="bk_pop" href="#clcn7.REF.frattini.2003.1740">Frattini et al 2003</a>]. Recently, recessive <a class="def" href="/books/n/gene/glossary/def-item/hypomorphic/">hypomorphic</a> <a class="def" href="/books/n/gene/glossary/def-item/intronic/">intronic</a> pathogenic variants in <i>TCIRG1</i> have been reported in an intermediate form of the disease [<a class="bk_pop" href="#clcn7.REF.sobacchi.2014.1646">Sobacchi et al 2014</a>, <a class="bk_pop" href="#clcn7.REF.palagano.2015.1814">Palagano et al 2015</a>]. These variants caused aberrant <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a>, but also allowed the production of a limited amount of normal transcript sufficient to dampen the severity of the disease usually associated with pathogenic variants in <i>TCIRG1</i>. In fact, three individuals with such variants at the <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> state reached adulthood in relatively good health, the major issues being recurrent nontraumatic fractures [<a class="bk_pop" href="#clcn7.REF.palagano.2015.1814">Palagano et al 2015</a>].</p></div><div id="clcn7.Autosomal_Dominant_Osteopetrosis_T"><h4>Autosomal Dominant Osteopetrosis Type II (ADOII)</h4><p>Although ADOII is sometimes called "benign osteopetrosis," as many as 60%-80% of individuals with radiologic signs of ADOII experience clinical problems (see <a class="figpopup" href="/books/NBK1127/figure/clcn7.F2/?report=objectonly" target="object" rid-figpopup="figclcn7F2" rid-ob="figobclcn7F2">Figure 2</a>).</p><div class="iconblock whole_rhythm clearfix ten_col fig" id="figclcn7F2" co-legend-rid="figlgndclcn7F2"><a href="/books/NBK1127/figure/clcn7.F2/?report=objectonly" target="object" title="Figure 2. " class="img_link icnblk_img figpopup" rid-figpopup="figclcn7F2" rid-ob="figobclcn7F2"><img class="small-thumb" src="/books/NBK1127/bin/clcn7-Image002.gif" src-large="/books/NBK1127/bin/clcn7-Image002.jpg" alt="Figure 2. " /></a><div class="icnblk_cntnt" id="figlgndclcn7F2"><h4 id="clcn7.F2"><a href="/books/NBK1127/figure/clcn7.F2/?report=objectonly" target="object" rid-ob="figobclcn7F2">Figure 2. </a></h4><p class="float-caption no_bottom_margin">ADOII x-rays Reprinted from B&#x000e9;nichou et al [2000] with permission from Elsevier</p></div></div><p>Onset of clinical and radiologic manifestations of ADOII is usually in late childhood or adolescence, although earlier occurrence has been reported. Osteosclerosis of the spine predominates, with a "sandwich vertebra" appearance, a diagnostic criterion for ADOII. Most <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals have a "bone-within-bone" appearance primarily in the iliac wings, but also in other bones. Transverse bands of sclerosis, perpendicular to the main axis, are often observed in long bones. Increase in the skull base density can be seen [<a class="bk_pop" href="#clcn7.REF.b_nichou.2000.87">B&#x000e9;nichou et al 2000</a>, <a class="bk_pop" href="#clcn7.REF.cleiren.2001.2861">Cleiren et al 2001</a>].</p><p>Clinical findings vary even within the same family [<a class="bk_pop" href="#clcn7.REF.chu.2006.1089">Chu et al 2006</a>]. In three families in which most <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals had mild ADOII, early-onset disease, anemia, and blindness caused by optic nerve compression were observed in some affected family members; this <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> has been called &#x0201c;intermediate osteopetrosis&#x0201d; because of its overlap with mild ARO.</p><p>The main complications affect the skeleton:</p><ul><li class="half_rhythm"><div><b>Fractures</b> occur in about 80% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals in the largest study, with a mean of three fractures per person [<a class="bk_pop" href="#clcn7.REF.b_nichou.2000.87">B&#x000e9;nichou et al 2000</a>]. Some individuals had more than ten fractures. The most frequently affected bone is the femur, but fractures occur in any long bone and in the posterior arch of the vertebrae, thereby inducing spondylolisthesis.</div></li><li class="half_rhythm"><div><b>Scoliosis</b> is seen in a number of cases.</div></li><li class="half_rhythm"><div><b>Hip osteoarthritis</b> is common (27%) and could be caused by the excessive toughness of the subchondral bone.</div></li><li class="half_rhythm"><div><b>Osteomyelitis</b> of the mandible is often associated with dental abscess or caries [<a class="bk_pop" href="#clcn7.REF.b_nichou.2000.87">B&#x000e9;nichou et al 2000</a>]. Septic osteitis or osteoarthritis at other localizations can also occur.</div></li></ul><p>Cranial nerve compression caused by osteosclerosis of the skull base is rare. Hearing loss and visual loss occurs in fewer than 5% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div></div><div id="clcn7.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p>Except for the following, no clear <a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a>-<a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> correlation exists:</p><ul><li class="half_rhythm"><div>Pathogenic <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a> variants and <a class="def" href="/books/n/gene/glossary/def-item/indel/">indel</a> and <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a> defects in <i>CLCN7</i> are more likely to cause ARO [Author, personal observation].</div></li><li class="half_rhythm"><div>The proportion of pathogenic variants in the C-terminal cystathionine &#x003b2;-synthase (CBS) domains of the H(+)/Cl(-) exchange transporter 7 is higher in ADOII than in ARO [Author, personal observation].</div></li></ul></div><div id="clcn7.Penetrance"><h3>Penetrance</h3><p>Depending on the population and the pathogenic variants studied, <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> ranges from 60% to 90% in families with ADOII [<a class="bk_pop" href="#clcn7.REF.bollerslev.1989.45">Bollerslev 1989</a>, <a class="bk_pop" href="#clcn7.REF.b_nichou.2000.87">B&#x000e9;nichou et al 2000</a>, <a class="bk_pop" href="#clcn7.REF.waguespack.2003.1513">Waguespack et al 2003</a>].</p></div><div id="clcn7.Prevalence"><h3>Prevalence</h3><p>The prevalence of ADOII has been estimated at up to 1:20,000 [<a class="bk_pop" href="#clcn7.REF.b_nichou.2001.647">B&#x000e9;nichou et al 2001</a>]. The disease is probably underdiagnosed in milder cases.</p><p>ARO is less common, with a prevalence around 1:250,000. Higher frequencies are reported in specific geographic areas, most likely as a result of a <a class="def" href="/books/n/gene/glossary/def-item/founder-effect/">founder effect</a>: one in 3500 newborns in Chuvashiya and one in 14,000 newborns in the Mari population in Russia [<a class="bk_pop" href="#clcn7.REF.bliznetz.2009.664">Bliznetz et al 2009</a>]; about 5.4:100,000 births in the Middle East [<a class="bk_pop" href="#clcn7.REF.souraty.2007.188">Souraty et al 2007</a>]. Higher frequencies are also registered in Costa Rica [<a class="bk_pop" href="#clcn7.REF.sobacchi.2001.1767">Sobacchi et al 2001</a>] and in the Swedish province of V&#x000e4;sterbotten [<a class="bk_pop" href="#clcn7.REF.pangrazio.2013.1041">Pangrazio et al 2013</a>].</p></div></div><div id="clcn7.Genetically_Related_Allelic_Disord"><h2 id="_clcn7_Genetically_Related_Allelic_Disord_">Genetically Related (Allelic) Disorders</h2><p>No phenotypes other than those discussed in this <i>GeneReview</i> are known to be associated with pathogenic variants in <i>CLCN7</i>.</p></div><div id="clcn7.Differential_Diagnosis"><h2 id="_clcn7_Differential_Diagnosis_">Differential Diagnosis</h2><div id="clcn7.Autosomal_Recessive_Osteopetrosis"><h3>Autosomal Recessive Osteopetrosis</h3><p><b>ARO secondary to <i>TCIRG1</i> pathogenic variants</b> (OMIM <a href="http://omim.org/entry/259700" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">259700</a>). More than 50% of ARO is caused by pathogenic variants in <i>TCIRG1</i>. ARO caused by <i>TCIRG1</i> pathogenic variants can be distinguished from <i>CLCN7</i>-related disease [<a class="bk_pop" href="#clcn7.REF.frattini.2000.343">Frattini et al 2000</a>, <a class="bk_pop" href="#clcn7.REF.kornak.2000.2059">Kornak et al 2000</a>] based on the higher frequency of neurodevelopmental delay and seizures in the latter form of osteopetrosis.</p><p><b>Osteoclast-poor ARO.</b> Osteoclast-poor ARO is characterized by onset within the first year of life and typical ARO manifestations. Investigation of a bone biopsy is prerequisite for a reliable diagnosis. However, <i>TNFSF11</i> (OMIM <a href="http://omim.org/entry/259710" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">259710</a>) pathogenic variants cause a slight T-cell defect and <i>TNFRSF11A</i> (OMIM <a href="http://omim.org/entry/612301" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">612301</a>) pathogenic variants can lead to hypogammaglobulinemia similar to a common variable immune deficiency (CVID) [<a class="bk_pop" href="#clcn7.REF.sobacchi.2007.960">Sobacchi et al 2007</a>, <a class="bk_pop" href="#clcn7.REF.guerrini.2008.64">Guerrini et al 2008</a>]. Ruling out a <i>TNFSF11</i> -related ARO is crucial since HSC transplantation is not successful in these <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p><p><b>ARO with renal tubular acidosis (RTA)</b> (OMIM <a href="http://omim.org/entry/259730" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">259730</a>). The onset of ARO with RTA is usually later than in the malignant infantile form of ARO and the disease course is milder. In addition to the generalized osteosclerosis, cerebral calcifications are typical and may be associated with intellectual disability [<a class="bk_pop" href="#clcn7.REF.jacquemin.1998.662">Jacquemin et al 1998</a>]. Pathogenic variants are found in <i>CA2</i>, the <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> encoding carbonic anhydrase 2 [<a class="bk_pop" href="#clcn7.REF.bolt.2005.e71">Bolt et al 2005</a>].</p><p><b>ARO secondary to <i>OSTM1</i> pathogenic variants</b> (OMIM <a href="http://omim.org/entry/259720" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">259720</a>). Approximately 4% of ARO is caused by pathogenic variants in <i>OSTM1</i>. <i>OSTM1</i> pathogenic variants cause an extremely severe form of ARO with CNS involvement [<a class="bk_pop" href="#clcn7.REF.pangrazio.2006.1098">Pangrazio et al 2006</a>]. Deletions in the OSTM1 <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> have also been observed [<a class="bk_pop" href="#clcn7.REF.ott.2013.292">Ott et al 2013</a>].</p><p><b>ARO secondary to <i>PLEKHM1</i> pathogenic variants</b> (OMIM <a href="http://omim.org/entry/611497" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">611497</a>). Two individuals with <i>PLEKHM1</i> pathogenic variants have been described to date. The <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> appears to be very mild and can regress with increasing age [<a class="bk_pop" href="#clcn7.REF.van_wesenbeeck.2007.919">Van Wesenbeeck et al 2007</a>].</p><p><b>ARO secondary to <i>SNX10</i> pathogenic variants</b> (OMIM <a href="http://omim.org/entry/615085" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">615085</a>). Approximately 4% of ARO is caused by pathogenic variants in <i>SNX10</i>; in particular<i>,</i> &#x0201c;V&#x000e4;sterbottenian osteopetrosis&#x0201d; is caused by pathogenic variants in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>. This form of ARO appears to be slightly less severe than the <i>CLCN7</i>-related form. However, loss of vision, anemia, and bone fragility are frequently observed, warranting the use of HSCT [<a class="bk_pop" href="#clcn7.REF.aker.2012.221">Aker et al 2012</a>, <a class="bk_pop" href="#clcn7.REF.pangrazio.2013.1041">Pangrazio et al 2013</a>].</p><p>See <a href="http://www.omim.org/phenotypicSeries/PS259700" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Osteopetrosis, autosomal recessive: OMIM Phenotypic Series</a> to view genes associated with this <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> in OMIM</p></div><div id="clcn7.Mild_ARO"><h3>Mild ARO</h3><p><b>ARO secondary to <a class="def" href="/books/n/gene/glossary/def-item/intronic/">intronic</a> <i>TCIRG1</i> pathogenic variants</b> (OMIM <a href="http://omim.org/entry/259700" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">259700</a>). A mild form of ARO can be caused by deep intronic or splice-site variants in <i>TCIRG1</i> [<a class="bk_pop" href="#clcn7.REF.sobacchi.2014.1646">Sobacchi et al 2014</a>, <a class="bk_pop" href="#clcn7.REF.palagano.2015.1814">Palagano et al 2015</a>]. This form can be very similar to <i>CLCN7</i>-related IAO or ADOII.</p></div><div id="clcn7.Autosomal_Dominant_Osteopetrosis"><h3>Autosomal Dominant Osteopetrosis</h3><p><b>Autosomal dominant osteopetrosis type I (ADOI)</b> (OMIM <a href="http://omim.org/entry/607634" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">607634</a>). Osteosclerosis in ADOI is most pronounced in the skull vault and does not lead to sandwich vertebrae. It is debated whether this disease entity should be called endosteal hyperostosis or high bone mass disorder, as osteopetrosis should be reserved for osteoclast-related disorders. ADOI is not associated with an increased fracture rate. Pathogenic variants in <i>LRP5</i> are causative [<a class="bk_pop" href="#clcn7.REF.van_wesenbeeck.2003.763">Van Wesenbeeck et al 2003</a>].</p><p>See <a href="http://www.omim.org/phenotypicSeries/PS607634" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Osteopetrosis, autosomal dominant: OMIM Phenotypic Series</a> to view genes associated with this <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> in OMIM.</p></div><div id="clcn7.Other"><h3>Other</h3><p><b>Pyknodysostosis</b> (OMIM <a href="http://omim.org/entry/265800" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">265800</a>). Affected individuals usually have small stature (adult height &#x0003c;150 cm), frontal bossing, wormian bones, a persistent (open) anterior fontanelle, and acroosteolysis of the terminal phalanges [<a class="bk_pop" href="#clcn7.REF.vanhoenacker.2000.1423">Vanhoenacker et al 2000</a>]. The bones are generally sclerotic and prone to fractures. In some patients the clinical presentation can resemble IAO [<a class="bk_pop" href="#clcn7.REF.pangrazio.2014.122">Pangrazio et al 2014</a>]. Pyknodysostosis is caused by pathogenic variants in <i>CTSK</i>, the <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> encoding cathepsin K [<a class="bk_pop" href="#clcn7.REF.gelb.1996.1236">Gelb et al 1996</a>], and is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner.</p><p><a href="/books/n/gene/sost/"><b><i>SOST</i>-related sclerosing bone dysplasias</b></a><b>,</b> including van Buchem disease and sclerosteosis, is characterized by moderate to gross skull hyperostosis leading to cranial nerve dysfunction, mandibular enlargement, and generalized osteosclerosis. Sclerosteosis also comprises syndactyly and tall stature and can be lethal as a result of increased intracranial pressure [<a class="bk_pop" href="#clcn7.REF.hamersma.2003.192">Hamersma et al 2003</a>]. The <i>SOST</i>-related sclerosing bone dysplasias are inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner.</p><p><a href="/books/n/gene/cranio-md/"><b>Autosomal dominant craniometaphyseal dysplasia</b></a>
<b>(AD-CMD).</b> The clinical hallmark of CMD is skull hyperostosis leading to deep-set eyes and paranasal bossing. Facial nerve palsy is common and occurs more frequently than optic nerve compression [<a class="bk_pop" href="#clcn7.REF.braun.2001.74">Braun et al 2001</a>]. The femur shows a modeling defect, but no osteosclerosis. Susceptibility to fractures is not increased. Pathogenic variants in <i>ANKH</i> are causative [<a class="bk_pop" href="#clcn7.REF.n_rnberg.2001.37">N&#x000fc;rnberg et al 2001</a>].</p><p><b>Autosomal recessive craniometaphyseal dysplasia (AR-CMD)</b> (OMIM <a href="http://omim.org/entry/218400" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">218400</a>). Affected individuals show typical features of CMD (macrocephaly, hearing loss, skull hyperostosis with paranasal bossing, metaphyseal widening) but less pronounced calvarial thickening [<a class="bk_pop" href="#clcn7.REF.iughetti.2000.482">Iughetti et al 2000</a>]. Due to diaphyseal osteosclerosis the disorder can occasionally resemble mild forms of osteopetrosis. Pathogenic variants in <i>GJA1</i> are causative [<a class="bk_pop" href="#clcn7.REF.hu.2013.e73576">Hu et al 2013</a>].</p><p><b>Dysosteosclerosis.</b> Short stature, sandwich vertebrae, platyspondyly, metaphyseal widening and sclerosis, and often also diaphyseal thickening are characteristic of dysosteosclerosis. <a class="bk_pop" href="#clcn7.REF.campeau.2012.4904">Campeau et al [2012]</a> identified <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> <i>SLC29A3</i> (OMIM <a href="http://omim.org/entry/612373" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">612373</a>) variants in two individuals with dysosteosclerosis. The <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> caused by deep <a class="def" href="/books/n/gene/glossary/def-item/intronic/">intronic</a> <i>TCIRG1</i> pathogenic variants can look similar [U Kornak, unpublished observation].</p><p><b>Leukocyte adhesion deficiency type III (LAD-III)</b> (OMIM <a href="http://omim.org/entry/612840" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">612840</a>). Affected individuals present with recurrent infections and a bleeding diathesis regardless of platelet or leukocyte count. Pathogenic variants in <i>FERMT3</i> (encoding fermitin family homolog 3) are causative. In some individuals with LAD-III, a high bone density can be found, since fermitin family homolog 3 (also referred to as kindlin-3) signaling is required for osteoclast-mediated bone resorption [<a class="bk_pop" href="#clcn7.REF.crazzolara.2015.1677">Crazzolara et al 2015</a>].</p></div></div><div id="clcn7.Management"><h2 id="_clcn7_Management_">Management</h2><p>Recently updated guidelines for diagnosis, therapy, and follow up are available; see <a href="#clcn7.Author_Information">Author Information</a>.</p><div id="clcn7.Evaluations_Following_Initial_Diag"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and needs in an individual diagnosed with infantile malignant <i>CLCN7</i>-related <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> osteopetrosis (ARO), the following evaluations are recommended:</p><ul><li class="half_rhythm"><div>Full blood cell count to evaluate for leukocytosis or leukocytopenia, thrombocytopenia, and anemia with low reticulocyte count</div></li><li class="half_rhythm"><div>Investigation of calcium concentrations in blood and urine to evaluate for hypocalcemia and secondary hyperparathyroidism</div></li><li class="half_rhythm"><div>Ultrasonography of abdomen to evaluate for hepatosplenomegaly</div></li><li class="half_rhythm"><div>MRI and/or CT of the neurocranium to evaluate for narrowed neuroforamina, hydrocephalus, and brain abnormalities in neuronopathic form of osteopetrosis</div></li><li class="half_rhythm"><div>Ophthalmologic examination including VEPs to evaluate for optic nerve atrophy</div></li><li class="half_rhythm"><div>Otorhinolaryngologic examination to evaluate for choanal stenosis</div></li><li class="half_rhythm"><div>EEG to detect pathologic changes associated with neurodegeneration; neurologic examination to evaluate development</div></li><li class="half_rhythm"><div>Consultation with a clinical geneticist and/or genetic counselor</div></li></ul></div><div id="clcn7.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><p>Due to the difference in severity, treatment strategies for ARO and ADOII differ. IAO lies between these two forms and has a variable prognosis. Therefore, treatment options must be evaluated on an individual basis.</p><div id="clcn7.ARO"><h4>ARO</h4><p><b>Hypocalcemic convulsions,</b> occurring in a substantial number of neonates as the first disease manifestation, should be treated by calcium supplementation. The management of calcium homeostasis may be difficult and recommendations are conflicting: whereas physiologic doses of calcium and vitamin D have been used to treat children with osteopetrosis who have rickets, restriction of calcium and vitamin D has been used to prevent progression of disease and hypercalcemic crisis following hematopoietic stem cell transplantation (HSCT). Treatment needs to take into account the particular situation of the <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual.</p><p><b>Bone marrow failure</b> may require erythrocyte or platelet transfusions (irradiated products). In the case of leukocytopenia and/or hypogammaglobulinemia, which may develop in a subset of individuals, antibiotics and immunoglobulins may be given in a prophylactic or therapeutic manner.</p><p>Newly diagnosed individuals should be transferred as soon as possible to a pediatric center experienced in allogeneic stem cell transplantation in this disease.</p><p><b>Sensory and neurologic manifestations</b> require the collaboration of pediatricians, pediatric neurologists, ophthalmologists, and psychologists. Surgical decompression of the optic nerve, a difficult procedure, has been performed with some success to prevent vision loss [<a class="bk_pop" href="#clcn7.REF.hwang.2000.328">Hwang et al 2000</a>].</p><p><b>Fractures</b> require treatment and surveillance by an experienced bone surgeon or orthopedist in collaboration with the treating pediatrician.</p><p><b>Dental.</b> Without HSCT, most children do not reach the age at which secondary dentition erupts. Children undergoing early HSCT may have normal secondary dentition despite defective primary dentition [<a class="bk_pop" href="#clcn7.REF.j_levik.2002.537">J&#x000e4;levik et al 2002</a>].</p><p>In some cases, defective tooth eruption, ankylosis, abscesses, and the formation of cysts and fistulas may require surgical intervention. Special attention is required to prevent mandibular osteomyelitis and extreme brittleness of the alveolar bone [<a class="bk_pop" href="#clcn7.REF.luzzi.2006.39">Luzzi et al 2006</a>].</p></div><div id="clcn7.ADOII"><h4>ADOII</h4><p>Orthopedic treatment is often required for fractures and arthritis. Post-surgical complications such as delayed union or non-union of fractures and infections are common (50%) because of the brittleness of the bones. Fractures near joints may require total joint arthroplasty [<a class="bk_pop" href="#clcn7.REF.strickland.2005.815">Strickland &#x00026; Berry 2005</a>].</p></div></div><div id="clcn7.Prevention_of_Primary_Manifestatio"><h3>Prevention of Primary Manifestations</h3><div id="clcn7.ARO_1"><h4>ARO</h4><p><b>Hematopoietic stem cell transplantation (HSCT).</b> Since the defective osteoclasts in osteopetrosis are of hematopoietic origin, allogeneic HSCT can be curative. Most manifestations (bone sclerosis, bone marrow failure, and extramedullary hematopoiesis) can be prevented or reversed by HSCT.</p><p>Secondary neurosensory impairments caused by nerve compression may be prevented by early transplantation, but not reversed when they are already present.</p><p>Primary neurologic problems and retinal degeneration developing in the neuronopathic form of ARO, however, are independent of the bone disease and therefore cannot be improved or prevented by HSCT. Persons with ARO resulting from <i>CLCN7</i> pathogenic variants who do not develop neurologic complications have been reported [<a class="bk_pop" href="#clcn7.REF.pangrazio.2010.e1071">Pangrazio et al 2010</a>; A Schulz and U Kornak, unpublished results].</p><p>It is highly important but difficult to exclude individuals with the neuronopathic form from this invasive treatment. On the other hand, HSCT should be performed as soon as possible in the majority of those without primary neurologic sequelae to prevent irreversible secondary complications, including visual impairment. The evaluation of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals and treatment by HSCT should therefore be performed in experienced pediatric centers after multidisciplinary evaluation to assess the severity of the disease and individual prognostic factors.</p><p>The outcome of HSCT in ARO has been analyzed in a retrospective survey of the European Society of Immunodeficiencies (ESID) and the European Group of Bone Marrow Transplantation (EBMT) [<a class="bk_pop" href="#clcn7.REF.sobacchi.2013.522">Sobacchi et al 2013</a>]. The five-year disease-free survival was estimated at 88% for genoidentical transplants, 80% for matched unrelated transplants, and 66% for haploidentical transplants [<a class="bk_pop" href="#clcn7.REF.sobacchi.2013.522">Sobacchi et al 2013</a>]. In a recently published report of 193 patients transplanted in various centers by a cyclophosphamide-based regimen, the five-year probabilities of survival were 62% after HLA-matched sib transplantation and 42% after alternative donor transplantation [<a class="bk_pop" href="#clcn7.REF.orchard.2015.270">Orchard et al 2015</a>]. A further improved outcome was most recently reported from three large transplant centers using a fludarabine-based conditioning regimen [<a class="bk_pop" href="#clcn7.REF.natsheh.2016.535">Natsheh et al 2016</a>; Schulz and Moshous, personal communication].</p><p>Note: Because <i>TCIRG1</i> pathogenic variants are more often the cause of ARO than are <i>CLCN7</i> pathogenic variants, the majority of HSCTs have been performed in infants with <i>TCIRG1</i> rather than <i>CLCN7</i> pathogenic variants. However, there appears to be no significant difference in treatment outcome between individuals with <i>TCIRG1</i> and <i>CLCN7</i> pathogenic variants [A Schulz et al, unpublished results].</p><p>The incidence of severe complications post-HSCT is high, particularly when alternative stem cell sources are used. Complications include rejection, delayed hematopoietic reconstitution, venous occlusive disease, pulmonary hypertension, and hypercalcemic crisis [<a class="bk_pop" href="#clcn7.REF.steward.2004.63">Steward et al 2004</a>, <a class="bk_pop" href="#clcn7.REF.corbacioglu.2006.547">Corbacioglu et al 2006</a>, <a class="bk_pop" href="#clcn7.REF.shroff.2012.1766">Shroff et al 2012</a>].</p><p>Cranial nerve dysfunction (visual impairment caused by optic nerve atrophy) is irreversible in most cases. In the authors' series including about 30 individuals, about two thirds of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals were visually impaired after successful transplantation [A Schulz, unpublished results].</p><p>Progressive neurologic sequelae, developmental delay, and repeated seizures occur in a subset of individuals after successful HSCT [<a class="bk_pop" href="#clcn7.REF.steward.2003.87">Steward 2003</a>]. Severe neurologic manifestations other than visual impairment have been seen in about 10% of individuals in the authors' series [A Schulz, unpublished results].</p><p><b>Other.</b> Conservative treatment strategies include stimulation of host osteoclasts with calcium restriction, calcitriol, steroids, parathyroid hormone, and interferon [<a class="bk_pop" href="#clcn7.REF.kocher.2003.222">Kocher &#x00026; Kasser 2003</a>]. Since evidence for a favorable outcome in severe osteopetrosis is limited and because side effects are severe (particularly in infants), these drugs may be administered in special situations only.</p></div></div><div id="clcn7.Prevention_of_Secondary_Complicati"><h3>Prevention of Secondary Complications</h3><p><b>ARO.</b> Restricted intake of calcium and vitamin D just before, during, and following HSCT to prevent hypercalcemia is recommended.</p><p>Parents and patients should be informed about possible complications of the disease and recommendations for prevention should be given accordingly (e.g., severe CNS bleeding in patients with thrombocytopenia, pathologic fractures). Because of the heterogeneity of the disease, recommendations should be given on an individual basis.</p><p><b>ADOII.</b> Good routine dental care and oral hygiene may help prevent osteomyelitis of the mandible.</p></div><div id="clcn7.Surveillance"><h3>Surveillance</h3><p><b>ARO</b></p><ul><li class="half_rhythm"><div>The possible manifestations and complications of osteopetrosis require repeat investigations; however, no general recommendations are available for the extent and frequency of investigations. A blood cell count and an ophthalmologic examination should be performed once a year at a minimum in all individuals with ARO.</div></li><li class="half_rhythm"><div>In individuals who have undergone HSCT, surveillance should be coordinated by the transplantation center; chimerism analysis should be performed repeatedly, as secondary graft failures have been reported. However, such individuals may be free of disease manifestation even in the case of stable mixed chimerism, if a substantial part of blood cells are donor derived (i.e., coexistence of hematopoietic cells of donor and recipient origin).</div></li></ul><p><b>ADOII.</b> In ADOII, skeletal manifestations do not progress and therefore no special surveillance is necessary.</p></div><div id="clcn7.AgentsCircumstances_to_Avoid"><h3>Agents/Circumstances to Avoid</h3><p><b>ADOII</b></p><ul><li class="half_rhythm"><div>Activities with high fracture risk should be avoided.</div></li><li class="half_rhythm"><div>Orthopedic surgery should only be performed when absolutely necessary and the surgeon should be aware of potential complications and difficulties in handling osteopetrotic bone.</div></li></ul></div><div id="clcn7.Evaluation_of_Relatives_at_Risk"><h3>Evaluation of Relatives at Risk</h3><p>It is appropriate to clarify the genetic status of apparently asymptomatic older and younger sibs of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> of the <i>CLCN7</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>(s) in the family in order to identify as early as possible those who would benefit from prompt initiation of treatment and preventive measures.</p><p>See <a href="#clcn7.Related_Genetic_Counseling_Issues">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="clcn7.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>Search <a href="http://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.clinicaltrialsregister.eu/ctr-search/search" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">EU Clinical Trials Register</a> in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.</p></div><div id="clcn7.Other_1"><h3>Other</h3><p>Studies have been initiated to investigate the relation of <a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a> and clinical outcome after stem cell transplantation (see the <a href="https://esid.org/Working-Parties/Educational-Working-Party/Reports/2014-2015-Medium-term-fellowship-report" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">European Society of Immunodeficiencies</a> [ESID] and <a href="https://www.ebmt.org/working-parties/transplant-complications-working-party-tcwp" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">European Group of Bone Marrow Transplantation</a> [EBMT] websites).</p></div></div><div id="clcn7.Genetic_Counseling"><h2 id="_clcn7_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="clcn7.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p><i>CLCN7</i>-related osteopetrosis is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> or <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner.</p></div><div id="clcn7.Autosomal_Recessive_Inheritance"><h3>Autosomal Recessive Inheritance</h3><div id="clcn7.Risk_to_Family_Members"><h4>Risk to Family Members</h4><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The parents of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> child are obligate heterozygotes (i.e., carriers of one <i>CLCN7</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>).</div></li><li class="half_rhythm"><div>Heterozygotes (carriers) are asymptomatic; however, no systematic studies have been performed to evaluate for subtle changes in bone mass.</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>At conception, each sib of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual has a 25% chance of being affected, a 50% chance of being an asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and a 25% chance of being unaffected and not a carrier.</div></li><li class="half_rhythm"><div>Heterozygotes (carriers) are asymptomatic; however, no systematic studies have been performed to evaluate for subtle changes in bone mass.</div></li><li class="half_rhythm"><div>The limited data available suggest that in the presence of infantile malignant <i>CLCN7</i>-related recessive osteopetrosis (ARO), a similar presentation of the disease is expected in individuals of the same family; in particular, if the neuronopathic form of the disease was present in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>, a primary CNS involvement is likely to be present in other <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> sibs [Sobacchi, unpublished observation].</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>In general, individuals with ARO reproduce only if successfully treated by hematopoietic stem cell transplantation (HSCT).</div></li><li class="half_rhythm"><div>The offspring of an individual with <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> <i>CLCN7</i>-related osteopetrosis are obligate heterozygotes (carriers) for a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>CLCN7</i>.</div></li></ul><p><b>Other family members.</b> Each sib of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s parents is at a 50% risk of being a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> of a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>CLCN7</i>.</p></div><div id="clcn7.Carrier_Heterozygote_Detection"><h4>Carrier (Heterozygote) Detection</h4><p>Carrier testing for at-risk relatives requires prior identification of the <i>CLCN7</i> pathogenic variants in the family.</p></div></div><div id="clcn7.Autosomal_Dominant_Inheritance__Ri"><h3>Autosomal Dominant Inheritance &#x02013; Risk to Family Members</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>Most individuals diagnosed with <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> <i>CLCN7</i>-related osteopetrosis have an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> parent.</div></li><li class="half_rhythm"><div>A <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> <i>CLCN7</i>-related osteopetrosis may have the disorder as the result of a new <i>CLCN7</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>. The proportion of cases caused by <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> pathogenic variants is unknown.</div></li><li class="half_rhythm"><div>Recommendations for the evaluation of parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with an apparent <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> include x-ray investigation of the skeleton and <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> for the pathogenic variant identified in the proband. Evaluation of parents may determine that one is <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> but has escaped previous diagnosis because of failure by health care professionals to recognize the syndrome and/or a milder phenotypic presentation. Therefore, an apparently negative family history cannot be confirmed until appropriate evaluations have been performed.</div></li></ul><p>Note: If the parent is the individual in whom the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> first occurred, s/he may have <a class="def" href="/books/n/gene/glossary/def-item/somatic-mosaicism/">somatic mosaicism</a> for the variant and may be mildly/minimally <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>.</p><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The risk to the sibs of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> depends on the genetic status of the proband's parents:</div><ul><li class="half_rhythm"><div>If a parent of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> is <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> or has the <i>CLCN7</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, the risk to the sibs of inheriting the variant is 50%.</div></li><li class="half_rhythm"><div>When the parents are clinically unaffected, the risk to the sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> appears to be low.</div></li><li class="half_rhythm"><div>If the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> found in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> cannot be detected in the DNA of one of the parents, the risk to sibs is low, but greater than that of the general population because of the possibility of <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a>. Germline mosaicism has not been reported.</div></li></ul></li><li class="half_rhythm"><div>The clinical severity of <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> osteopetrosis type II (ADOII) may vary within a family.</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> Each child of an individual with <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> <i>CLCN7</i>-related osteopetrosis has a 50% chance of inheriting the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</p><p><b>Other family members.</b> The risk to other family members depends on the status of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s parents. If a parent has the <i>CLCN7</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, his or her family members may be at risk.</p></div><div id="clcn7.Related_Genetic_Counseling_Issues"><h3>Related Genetic Counseling Issues</h3><p>See Management, <a href="#clcn7.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</a> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p><p><b>Considerations in families with an apparent <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</b> When neither parent of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> condition has the pathogenic variant or clinical evidence of the disorder, it is likely that the proband has a <i>de novo</i> pathogenic variant. However, possible non-medical explanations including <a class="def" href="/books/n/gene/glossary/def-item/alternate-paternity/">alternate paternity</a> or maternity (e.g., with assisted reproduction) or undisclosed adoption could be explored.</p><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk, clarification of <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> status, and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>, are carriers, or at risk of being carriers.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="clcn7.Prenatal_Testing_and_Preimplantati"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p>Once the <i>CLCN7</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>(s) have been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> for <i>CLCN7</i>-related osteopetrosis are possible.</p><p>Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. While decisions regarding prenatal testing are the choice of the parents, discussion of these issues is appropriate.</p></div></div><div id="clcn7.Resources"><h2 id="_clcn7_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>The OsteoPETrosis Society (OPETS)</b></div><div><b>Phone:</b> 980-292-3921</div><div><b>Email:</b> osteopetrosispatient@gmail.com; janecastello.opets@gmail.com</div><div><a href="http://www.osteopetrosis.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.osteopetrosis.org</a></div></li><li class="half_rhythm"><div><b>National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)</b></div><div>1 AMS Circle</div><div>Bethesda MD 20892-3675</div><div><b>Phone:</b> 877-226-4267 (toll-free); 301-565-2966 (TTY)</div><div><b>Fax:</b> 301-718-6366</div><div><b>Email:</b> niamsinfo@mail.nih.gov</div><div><a href="http://www.niams.nih.gov" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.niams.nih.gov</a></div></li><li class="half_rhythm"><div><b>National Library of Medicine Genetics Home Reference</b></div><div><a href="http://ghr.nlm.nih.gov/condition/osteopetrosis" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Osteopetrosis</a></div></li><li class="half_rhythm"><div><b>European Society for Immunodeficiencies (ESID) Registry</b></div><div>Dr. Gerhard Kindle</div><div>University Medical Center Freiburg Centre of Chronic Immunodeficiency</div><div>Engesserstr. 4</div><div>79106 Freiburg </div><div>Germany</div><div><b>Phone:</b> 49-761-270-34450</div><div><b>Email:</b> esid-registry@uniklinik-freiburg.de</div><div><a href="http://esid.org/Working-Parties/Registry" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ESID Registry</a></div></li><li class="half_rhythm"><div><b>International Skeletal Dysplasia Registry</b></div><div>UCLA</div><div>615 Charles E. Young Drive</div><div>South Room 410</div><div>Los Angeles CA 90095-7358</div><div><b>Phone:</b> 310-825-8998</div><div><b>Fax:</b> 310-206-5266</div><div><b>Email:</b> Salon@mednet.ucla.edu</div><div><a href="https://www.uclahealth.org/ortho/isdr" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">International Skeletal Dysplasia Registry</a></div></li></ul></div><div id="clcn7.Molecular_Genetics"><h2 id="_clcn7_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="clcn7.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>CLCN7-Related Osteopetrosis: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1127/table/clcn7.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__clcn7.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_clcn7.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_clcn7.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_clcn7.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_clcn7.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_clcn7.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_clcn7.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_clcn7.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/1186" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>CLCN7</i></a></td><td headers="hd_b_clcn7.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=1186" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">16p13<wbr style="display:inline-block"></wbr>​.3</a></td><td headers="hd_b_clcn7.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/P51798" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">H(+)/Cl(-) exchange transporter 7</a></td><td headers="hd_b_clcn7.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://bipmed.iqm.unicamp.br/genes/CLCN7" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">CLCN7 database</a></td><td headers="hd_b_clcn7.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=CLCN7" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">CLCN7</a></td><td headers="hd_b_clcn7.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=CLCN7[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">CLCN7</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="clcn7.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="clcn7.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for CLCN7-Related Osteopetrosis (<a href="/omim/166600,602727,611490" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1127/table/clcn7.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__clcn7.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/166600" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">166600</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">OSTEOPETROSIS, AUTOSOMAL DOMINANT 2; OPTA2</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/602727" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">602727</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CHLORIDE CHANNEL 7; CLCN7</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/611490" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">611490</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">OSTEOPETROSIS, AUTOSOMAL RECESSIVE 4; OPTB4</td></tr></tbody></table></div></div><div id="clcn7.Molecular_Pathogenesis"><h3>Molecular Pathogenesis</h3><p>ARO, IAO, and ADOII are caused by osteoclast dysfunction. The osteoclast is a highly specialized cell with the unique ability to resorb large amounts of mineralized bone tissue. Like macrophages, osteoclasts are giant multinuclear cells formed by fusion of mononuclear hematopoietic precursors that subsequently differentiate under the influence of M-CSF and RANKL.</p><p>After attaching to the bone surface, a sealing zone that isolates the resorption lacuna from the extracellular environment is formed. Large quantities of acidic vesicles then fuse with the plasma membrane juxtaposed to the bone surface to create the ruffled membrane. This structure is exclusively found in osteoclasts and secretes large amounts of acid into the resorption lacuna, which therefore is also referred to as an "extracellular lysosome" [<a class="bk_pop" href="#clcn7.REF.teitelbaum.2003.638">Teitelbaum &#x00026; Ross 2003</a>]. The low pH is required to dissolve the bone mineral and for the optimal activity of acid hydrolases that degrade the bone matrix, particularly cathepsin K.</p><p>Most forms of human osteopetrosis for which the genetic causes have been identified so far are the result of defects in the acid secretion mechanism. The ClC-7 chloride channel resides in lysosomal vesicles and in the ruffled membrane and acts as a 2Cl<sup>-</sup>/1H<sup>+</sup> exchanger transporting negative charges into the resorption lacuna in parallel to the protons pumped in this extracellular space by the ruffled membrane v-type H<sup>+</sup>-ATPase [<a class="bk_pop" href="#clcn7.REF.kornak.2001.205">Kornak et al 2001</a>, <a class="bk_pop" href="#clcn7.REF.leisle.2011.2140">Leisle et al 2011</a>].</p><p><i>TCIRG1</i> encodes an important subunit of this H<sup>+</sup>-ATPase and carbonic anhydrase 2, encoded by <i>CA2</i>, generates the necessary protons in the osteoclast cytoplasm; thus, defects in these genes also cause osteopetrosis.</p><p>Pathogenic variants in <i>CLCN7</i> lead to a loss of chloride channel function of varying degree. In the most severe cases of ARO, H(+)/Cl(-) exchange transporter 7 (also known as ClC-7) is absent. As illustrated by a knockout mouse model, which shows degeneration of the CNS and the retina, a complete loss of the protein entails a strong risk for the neuronopathic form of ARO [<a class="bk_pop" href="#clcn7.REF.kornak.2001.205">Kornak et al 2001</a>, <a class="bk_pop" href="#clcn7.REF.steward.2003.87">Steward 2003</a>, <a class="bk_pop" href="#clcn7.REF.kasper.2005.1079">Kasper et al 2005</a>].</p><p>The less severe forms of osteopetrosis are thought to be caused by pathogenic variants that incompletely inactivate the protein. Pathogenic variants found in <i>ADOII</i> apparently have <a class="def" href="/books/n/gene/glossary/def-item/dominant-negative/">dominant-negative</a> effects. It has been shown that these pathogenic variants affect chloride channel function, as has been described for the Thomsen type of <a href="/books/n/gene/myotonia-c/">myotonia congenita</a>, caused by dominant pathogenic variants in <i>CLCN1</i> [<a class="bk_pop" href="#clcn7.REF.jentsch.2005b.779">Jentsch et al 2005b</a>]. Some <i>CLCN7</i> pathogenic variants have been reported to alter expression and subcellular localization of the protein. Electrophysiologic measurement of a ClC-7 variant localizing to the plasma membrane demonstrated that ADOII-causing pathogenic variants do not necessarily impair chloride currents, but do result in abnormal gating behavior of the channel [<a class="bk_pop" href="#clcn7.REF.leisle.2011.2140">Leisle et al 2011</a>].</p><p><b>Gene structure.</b> The most relevant <i>CLCN7</i> transcript (<a href="/nuccore/NM_001287.5" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_001287.5</a>, <a href="/CCDS/CcdsBrowse.cgi?REQUEST=GENEID&#x00026;DATA=1186" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">CCDS 32361.1</a>) contains a <a class="def" href="/books/n/gene/glossary/def-item/coding-region/">coding region</a> of 2418 bp subdivided into 25 exons. For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/NBK1127/#clcn7.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Pathogenic variants.</b> Pathogenic variants found in ARO comprise <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a> variants (7.4%), frameshifts caused by <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a> defects and indels (25.5%), <a class="def" href="/books/n/gene/glossary/def-item/in-frame/">in-frame</a> deletions (0.01%) and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants (66%). Approximately 28.7% of these pathogenic variants reside in the C-terminal CBS domains of the protein. A <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/contiguous-gene-deletion/">contiguous gene deletion</a> has also been identified in one individual with ARO [<a class="bk_pop" href="#clcn7.REF.pangrazio.2012.250">Pangrazio et al 2012</a>]. In <i>ADOII</i>, pathogenic variants comprise nonsense variants (2.5%), frameshifts (12.5%), inframe deletions (2.5%) and missense variants (82.5%). Approximately 45% of these pathogenic variants are found in the C-terminal CBS domains [Sobacchi, unpublished].</p><div id="clcn7.T.clcn7_variants_discussed_in_this" class="table"><h3><span class="label">Table 4. </span></h3><div class="caption"><p><i>CLCN7</i> Variants Discussed in This <i>GeneReview</i></p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1127/table/clcn7.T.clcn7_variants_discussed_in_this/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__clcn7.T.clcn7_variants_discussed_in_this_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_clcn7.T.clcn7_variants_discussed_in_this_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Variant Classification</th><th id="hd_h_clcn7.T.clcn7_variants_discussed_in_this_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change</th><th id="hd_h_clcn7.T.clcn7_variants_discussed_in_this_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change</th><th id="hd_h_clcn7.T.clcn7_variants_discussed_in_this_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_clcn7.T.clcn7_variants_discussed_in_this_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Benign</b></td><td headers="hd_h_clcn7.T.clcn7_variants_discussed_in_this_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1252G&#x0003e;A</td><td headers="hd_h_clcn7.T.clcn7_variants_discussed_in_this_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Val418Met</td><td headers="hd_h_clcn7.T.clcn7_variants_discussed_in_this_1_1_1_4" rowspan="4" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/nuccore/NM_001287.5" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_001287<wbr style="display:inline-block"></wbr>​.5</a><br /><a href="/protein/NP_001278.1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_001278<wbr style="display:inline-block"></wbr>​.1</a></td></tr><tr><td headers="hd_h_clcn7.T.clcn7_variants_discussed_in_this_1_1_1_1" rowspan="3" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Pathogenic</b></td><td headers="hd_h_clcn7.T.clcn7_variants_discussed_in_this_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.296A&#x0003e;G</td><td headers="hd_h_clcn7.T.clcn7_variants_discussed_in_this_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Tyr99Cys</td></tr><tr><td headers="hd_h_clcn7.T.clcn7_variants_discussed_in_this_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.643G&#x0003e;A</td><td headers="hd_h_clcn7.T.clcn7_variants_discussed_in_this_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Gly215Arg</td></tr><tr><td headers="hd_h_clcn7.T.clcn7_variants_discussed_in_this_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.2299C&#x0003e;T</td><td headers="hd_h_clcn7.T.clcn7_variants_discussed_in_this_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg767Trp</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin"><i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b>
<i>CLCN7</i> encodes the 805-amino acid H(+)/Cl(-) exchange transporter 7 (ClC-7), which resides in late endosomes and lysosomes of most cell types. In osteoclasts, the protein is translocated to the ruffled membrane. Like the other CLC channels, ClC-7 contains two C-terminal CBS domains, assumed to be involved in protein-protein interaction. This interaction may facilitate the formation of the functional channel dimers. CLC channels are not pure chloride channels but rather function as chloride/proton antiporters [<a class="bk_pop" href="#clcn7.REF.jentsch.2005a.2039">Jentsch et al 2005a</a>]. The OSTM1 protein is a subunit of the functional CLC channels and influences their behavior [<a class="bk_pop" href="#clcn7.REF.lange.2006.220">Lange et al 2006</a>, <a class="bk_pop" href="#clcn7.REF.leisle.2011.2140">Leisle et al 2011</a>]. When driven to the plasma membrane the protein complex shows slow gating and outwardly rectifying chloride currents [<a class="bk_pop" href="#clcn7.REF.leisle.2011.2140">Leisle et al 2011</a>].</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> A complete loss of the ClC-7 protein abolished osteoclast resorptive activity in mice with <i>Clcn7</i><sup>&#x02212;/&#x02212;</sup> osteoclasts; similarly, some individuals with malignant infantile osteopetrosis had one <a class="def" href="/books/n/gene/glossary/def-item/null/">null</a> <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> [<a class="bk_pop" href="#clcn7.REF.kornak.2001.205">Kornak et al 2001</a>]. The situation for <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants is less clear. Only a minority of ClC-7 mutants have been tested for their stability and subcellular distribution. The tested pathogenic missense variants show variable effects [<a class="bk_pop" href="#clcn7.REF.schulz.2010.e12585">Schulz et al 2010</a>, <a class="bk_pop" href="#clcn7.REF.leisle.2011.2140">Leisle et al 2011</a>]. Among the pathogenic variants associated with ADOII tested in vitro (10 of 40 total variants), the majority alter the electrophysiologic properties of the channel [<a class="bk_pop" href="#clcn7.REF.leisle.2011.2140">Leisle et al 2011</a>]. Interestingly, some of these variants showed normal current amplitudes and even accelerated gating. These alterations are thought to lead to the variable attenuation of osteoclast activity &#x02013; giving rise to the variability of the clinical course [<a class="bk_pop" href="#clcn7.REF.chu.2006.1089">Chu et al 2006</a>, <a class="bk_pop" href="#clcn7.REF.del_fattore.2006.315">Del Fattore et al 2006</a>].</p></div></div><div id="clcn7.References"><h2 id="_clcn7_References_">References</h2><div id="clcn7.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="clcn7.REF.aker.2012.221">Aker M, Rouvinski A, Hashavia S, Ta-Shma A, Shaag A, Zenvirt S, Israel S, Weintraub M, Taraboulos A, Bar-Shavit Z, Elpeleg O. An SNX10 mutation causes malignant osteopetrosis of infancy. <span><span class="ref-journal">J Med Genet. </span>2012;<span class="ref-vol">49</span>:221–6.</span> [<a href="/pubmed/22499339" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22499339</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="clcn7.REF.b_nichou.2001.647">B&#x000e9;nichou O, Cleiren E, Gram J, Bollerslev J, de Vernejoul MC, Van Hul W. Mapping of autosomal dominant osteopetrosis type II (Albers-Sch&#x000f6;nberg disease) to chromosome 16p13.3. <span><span class="ref-journal">Am J Hum Genet. </span>2001;2001;<span class="ref-vol">69</span>:647–54.</span> [<a href="/pmc/articles/PMC1235505/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1235505</span></a>] [<a href="/pubmed/11468688" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11468688</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="clcn7.REF.b_nichou.2000.87">B&#x000e9;nichou OD, Laredo JD, de Vernejoul MC. Type II autosomal dominant osteopetrosis (Albers-Sch&#x000f6;nberg disease): clinical and radiological manifestations in 42 patients. <span><span class="ref-journal">Bone. </span>2000;<span class="ref-vol">26</span>:87–93.</span> [<a href="/pubmed/10617161" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10617161</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="clcn7.REF.bliznetz.2009.664">Bliznetz EA, Tverskaya SM, Zinchenko RA, Abrukova AV, Savaskina EN, Nikulin MV, Kirillov AG, Ginter EK, Polyakov AV. Genetic analysis of autosomal recessive osteopetrosis in Chuvashiya: the unique splice site mutation in TCIRG1 gene spread by the founder effect. <span><span class="ref-journal">Eur J Hum Genet. </span>2009;<span class="ref-vol">17</span>:664–72.</span> [<a href="/pmc/articles/PMC2986262/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2986262</span></a>] [<a href="/pubmed/19172990" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19172990</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="clcn7.REF.bollerslev.1989.45">Bollerslev J. Autosomal dominant osteopetrosis: bone metabolism and epidemiological, clinical, and hormonal aspects. <span><span class="ref-journal">Endocr Rev. </span>1989;<span class="ref-vol">10</span>:45–67.</span> [<a href="/pubmed/2666111" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2666111</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="clcn7.REF.bolt.2005.e71">Bolt RJ, Wennink JM, Verbeke JI, Shah GN, Sly WS, B&#x000f6;kenkamp A. Carbonic anhydrase type II deficiency. <span><span class="ref-journal">Am J Kidney Dis. </span>2005;<span class="ref-vol">46</span>(A50):e71–3.</span> [<a href="/pubmed/16265785" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16265785</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="clcn7.REF.braun.2001.74">Braun HS, Nurnberg P, Tinschert S. Metaphyseal dysplasia: a new autosomal dominant type in a large German kindred. <span><span class="ref-journal">Am J Med Genet. </span>2001;<span class="ref-vol">101</span>:74–7.</span> [<a href="/pubmed/11343343" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11343343</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="clcn7.REF.campeau.2012.4904">Campeau PM, Lu JT, Sule G, Jiang MM, Bae Y, Madan S, H&#x000f6;gler W, Shaw NJ, Mumm S, Gibbs RA, Whyte MP, Lee BH. Whole-exome sequencing identifies mutations in the nucleoside transporter gene SLC29A3 in dysosteosclerosis, a form of osteopetrosis. <span><span class="ref-journal">Hum Mol Genet. </span>2012;<span class="ref-vol">21</span>:4904–9.</span> [<a href="/pmc/articles/PMC3607481/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3607481</span></a>] [<a href="/pubmed/22875837" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22875837</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="clcn7.REF.camposxavier.2003.186">Campos-Xavier AB, Saraiva JM, Ribeiro LM, Munnich A, Cormier-Daire V. Chloride channel 7 (CLCN7) gene mutations in intermediate autosomal recessive osteopetrosis. <span><span class="ref-journal">Hum Genet. </span>2003;<span class="ref-vol">112</span>:186–9.</span> [<a href="/pubmed/12522560" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12522560</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="clcn7.REF.chu.2006.1089">Chu K, Snyder R, Econs MJ. Disease status in autosomal dominant osteopetrosis type 2 is determined by osteoclastic properties. <span><span class="ref-journal">J Bone Miner Res. </span>2006;<span class="ref-vol">21</span>:1089–97.</span> [<a href="/pubmed/16813529" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16813529</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="clcn7.REF.cleiren.2001.2861">Cleiren E, B&#x000e9;nichou O, Van Hul E, Gram J, Bollerslev J, Singer FR, Beaverson K, Aledo A, Whyte MP, Yoneyama T, deVernejoul MC, Van Hul W. Albers-Schonberg disease (autosomal dominant osteopetrosis, type II) results from mutations in the ClCN7 chloride channel gene. <span><span class="ref-journal">Hum Mol Genet. </span>2001;<span class="ref-vol">10</span>:2861–7.</span> [<a href="/pubmed/11741829" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11741829</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="clcn7.REF.corbacioglu.2006.547">Corbacioglu S, H&#x000f6;nig M, Lahr G, St&#x000f6;hr S, Berry G, Friedrich W, Schulz AS. Stem cell transplantation in children with infantile osteopetrosis is associated with a high incidence of VOD, which could be prevented with defibrotide. <span><span class="ref-journal">Bone Marrow Transplant. </span>2006;<span class="ref-vol">38</span>:547–53.</span> [<a href="/pubmed/16953210" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16953210</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="clcn7.REF.crazzolara.2015.1677">Crazzolara R, Maurer K, Schulze H, Zieger B, Zustin J, Schulz AS. A new mutation in the KINDLIN-3 gene ablates integrin-dependent leukocyte, platelet, and osteoclast function in a patient with leukocyte adhesion deficiency-III. <span><span class="ref-journal">Pediatr Blood Cancer. </span>2015;<span class="ref-vol">62</span>:1677–9.</span> [<a href="/pubmed/25854317" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25854317</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="clcn7.REF.del_fattore.2006.315">Del Fattore A, Peruzzi B, Rucci N, Recchia I, Cappariello A, Longo M, Fortunati D, Ballanti P, Iacobini M, Luciani M, Devito R, Pinto R, Caniglia M, Lanino E, Messina C, Cesaro S, Letizia C, Bianchini G, Fryssira H, Grabowski P, Shaw N, Bishop N, Hughes D, Kapur RP, Datta HK, Taranta A, Fornari R, Migliaccio S, Teti A. Clinical, genetic, and cellular analysis of 49 osteopetrotic patients: implications for diagnosis and treatment. <span><span class="ref-journal">J Med Genet. </span>2006;<span class="ref-vol">43</span>:315–25.</span> [<a href="/pmc/articles/PMC2563229/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2563229</span></a>] [<a href="/pubmed/16118345" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16118345</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="clcn7.REF.dozier.2005.762">Dozier TS, Duncan IM, Klein AJ, Lambert PR, Key LL Jr. Otologic manifestations of malignant osteopetrosis. <span><span class="ref-journal">Otol Neurotol. </span>2005;<span class="ref-vol">26</span>:762–6.</span> [<a href="/pubmed/16015181" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16015181</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="clcn7.REF.frattini.2000.343">Frattini A, Orchard PJ, Sobacchi C, Giliani S, Abinun M, Mattsson JP, Keeling DJ, Andersson AK, Wallbrandt P, Zecca L, Notarangelo LD, Vezzoni P, Villa A. Defects in TCIRG1 subunit of the vacuolar proton pump are responsible for a subset of human autosomal recessive osteopetrosis. <span><span class="ref-journal">Nat Genet. </span>2000;<span class="ref-vol">25</span>:343–6.</span> [<a href="/pubmed/10888887" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10888887</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="clcn7.REF.frattini.2003.1740">Frattini A, Pangrazio A, Susani L, Sobacchi C, Mirolo M, Abinun M, Andolina M, Flanagan A, Horwitz EM, Mihci E, Notarangelo LD, Ramenghi U, Teti A, Van Hove J, Vujic D, Young T, Albertini A, Orchard PJ, Vezzoni P, Villa A. Chloride channel ClCN7 mutations are responsible for severe recessive, dominant, and intermediate osteopetrosis. <span><span class="ref-journal">J Bone Miner Res. </span>2003;<span class="ref-vol">18</span>:1740–7.</span> [<a href="/pubmed/14584882" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14584882</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="clcn7.REF.gelb.1996.1236">Gelb BD, Shi GP, Chapman HA, Desnick RJ. Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. <span><span class="ref-journal">Science. </span>1996;<span class="ref-vol">273</span>:1236–8.</span> [<a href="/pubmed/8703060" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8703060</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="clcn7.REF.guerrini.2008.64">Guerrini MM, Sobacchi C, Cassani B, Abinun M, Kilic SS, Pangrazio A, Moratto D, Mazzolari E, Clayton-Smith J, Orchard P, Coxon FP, Helfrich MH, Crockett JC, Mellis D, Vellodi A, Tezcan I, Notarangelo J, Rogers MJ, Vezzoni P, Villa A, Frattini A. Humanosteoclast-poor osteopetrosis with hypogammaglobulinemia due to TNFRSF11A (RANK) mutations. <span><span class="ref-journal">Am J Hum Genet. </span>2008;<span class="ref-vol">83</span>:64–76.</span> [<a href="/pmc/articles/PMC2443850/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2443850</span></a>] [<a href="/pubmed/18606301" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18606301</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="clcn7.REF.hamersma.2003.192">Hamersma H, Gardner J, Beighton P. The natural history of sclerosteosis. <span><span class="ref-journal">Clin Genet. </span>2003;<span class="ref-vol">63</span>:192–7.</span> [<a href="/pubmed/12694228" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12694228</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="clcn7.REF.helfrich.2005.115">Helfrich MH. Osteoclast diseases and dental abnormalities. <span><span class="ref-journal">Arch Oral Biol. </span>2005;<span class="ref-vol">50</span>:115–22.</span> [<a href="/pubmed/15721137" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15721137</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="clcn7.REF.hu.2013.e73576">Hu Y, Chen IP, de Almeida S, Tiziani V, Do Amaral CM, Gowrishankar K, Passos-Bueno MR, Reichenberger EJ. A novel autosomal recessive GJA1 missense mutation linked to Craniometaphyseal dysplasia. <span><span class="ref-journal">PLoS One. </span>2013;<span class="ref-vol">8</span>:e73576.</span> [<a href="/pmc/articles/PMC3741164/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3741164</span></a>] [<a href="/pubmed/23951358" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23951358</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="clcn7.REF.hwang.2000.328">Hwang JM, Kim IO, Wang KC. Complete visual recovery in osteopetrosis by early optic nerve decompression. <span><span class="ref-journal">Pediatr Neurosurg. </span>2000;<span class="ref-vol">33</span>:328–32.</span> [<a href="/pubmed/11182645" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11182645</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="clcn7.REF.iughetti.2000.482">Iughetti P, Alonso LG, Wilcox W, Alonso N, Passos-Bueno MR. Mapping of the autosomal recessive (AR) craniometaphyseal dysplasia locus to chromosome region 6q21-22 and confirmation of genetic heterogeneity for mild AR spondylocostal dysplasia. <span><span class="ref-journal">Am J Med Genet. </span>2000;<span class="ref-vol">95</span>:482–91.</span> [<a href="/pubmed/11146471" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11146471</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="clcn7.REF.jacquemin.1998.662">Jacquemin C, Mullaney P, Svedberg E. Marble brain syndrome: osteopetrosis, renal acidosis and calcification of the brain. <span><span class="ref-journal">Neuroradiology. </span>1998;<span class="ref-vol">40</span>:662–3.</span> [<a href="/pubmed/9833897" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9833897</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="clcn7.REF.j_levik.2002.537">J&#x000e4;levik B, Fasth A, Dahll&#x000f6;f G. Dental development after successful treatment of infantile osteopetrosis with bone marrow transplantation. <span><span class="ref-journal">Bone Marrow Transplant. </span>2002;<span class="ref-vol">29</span>:537–40.</span> [<a href="/pubmed/11960278" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11960278</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="clcn7.REF.jentsch.2005a.2039">Jentsch TJ, Maritzen T, Zdebik AA. Chloride channel diseases resulting from impaired transepithelial transport or vesicular function. <span><span class="ref-journal">J Clin Invest. </span>2005a;<span class="ref-vol">115</span>:2039–46.</span> [<a href="/pmc/articles/PMC1180548/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1180548</span></a>] [<a href="/pubmed/16075045" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16075045</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="clcn7.REF.jentsch.2005b.779">Jentsch TJ, Poet M, Fuhrmann JC, Zdebik AA. Physiological functions of CLC. <span><span class="ref-journal">Annu Rev Physiol. </span>2005b;<span class="ref-vol">67</span>:779–807.</span> [<a href="/pubmed/15709978" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15709978</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="clcn7.REF.kasper.2005.1079">Kasper D, Planells-Cases R, Fuhrmann JC, Scheel O, Zeitz O, Ruether K, Schmitt A, Poet M, Steinfeld R, Schweizer M, Kornak U, Jentsch TJ. Loss of the chloride channel ClC-7 leads to lysosomal storage disease and neurodegeneration. <span><span class="ref-journal">EMBO J. </span>2005;<span class="ref-vol">24</span>:1079–91.</span> [<a href="/pmc/articles/PMC554126/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC554126</span></a>] [<a href="/pubmed/15706348" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15706348</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="clcn7.REF.kocher.2003.222">Kocher MS, Kasser JR. Osteopetrosis. <span><span class="ref-journal">Am J Orthop. </span>2003;<span class="ref-vol">32</span>:222–8.</span> [<a href="/pubmed/12772872" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12772872</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="clcn7.REF.kornak.2001.205">Kornak U, Kasper D, Bosl MR, Kaiser E, Schweizer M, Schulz A, Friedrich W, Delling G, Jentsch TJ. Loss of the ClC-7 chloride channel leads to osteopetrosis in mice and man. <span><span class="ref-journal">Cell. </span>2001;<span class="ref-vol">104</span>:205–15.</span> [<a href="/pubmed/11207362" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11207362</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="clcn7.REF.kornak.2000.2059">Kornak U, Schulz A, Friedrich W, Uhlhaas S, Kremens B, Voit T, Hasan C, Bode U, Jentsch TJ, Kubisch C. Mutations in the a3 subunit of the vacuolar H(+)-ATPase cause infantile malignant osteopetrosis. <span><span class="ref-journal">Hum Mol Genet. </span>2000;<span class="ref-vol">9</span>:2059–63.</span> [<a href="/pubmed/10942435" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10942435</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="clcn7.REF.lange.2006.220">Lange PF, Wartosch L, Jentsch TJ, Fuhrmann JC. ClC-7 requires Ostm1 as a beta-subunit to support bone resorption and lysosomal function. <span><span class="ref-journal">Nature. </span>2006;<span class="ref-vol">440</span>:220–3.</span> [<a href="/pubmed/16525474" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16525474</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="clcn7.REF.leisle.2011.2140">Leisle L, Ludwig CF, Wagner FA, Jentsch TJ, Stauber T. ClC-7 is a slowly voltage-gated 2Cl(-)/1H(+)-exchanger and requires Ostm1 for transport activity. <span><span class="ref-journal">EMBO J. </span>2011;<span class="ref-vol">30</span>:2140–52.</span> [<a href="/pmc/articles/PMC3117652/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3117652</span></a>] [<a href="/pubmed/21527911" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21527911</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="clcn7.REF.luzzi.2006.39">Luzzi V, Consoli G, Daryanani V, Santoro G, Sfasciotti GL, Polimeni A. Malignant infantile osteopetrosis: dental effects in paediatric patients. Case reports. <span><span class="ref-journal">Eur J Paediatr Dent. </span>2006;<span class="ref-vol">7</span>:39–44.</span> [<a href="/pubmed/16646644" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16646644</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="clcn7.REF.natsheh.2016.535">Natsheh J, Drozdinsky G, Simanovsky N, Lamdan R, Erlich O, Gorelik N, Or R, Weintraub M, Stepensky P. Improved outcomes of hematopoietic stem cell transplantation in patients with infantile malignant osteopetrosis using fludarabine-based conditioning. <span><span class="ref-journal">Pediatr Blood Cancer. </span>2016;<span class="ref-vol">63</span>:535–40.</span> [<a href="/pubmed/26485304" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26485304</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="clcn7.REF.n_rnberg.2001.37">N&#x000fc;rnberg P, Thiele H, Chandler D, H&#x000f6;hne W, Cunningham ML, Ritter H, Leschik G, Uhlmann K, Mischung C, Harrop K, Goldblatt J, Borochowitz ZU, Kotzot D, Westermann F, Mundlos S, Braun HS, Laing N, Tinschert S. Heterozygous mutations in ANKH, the human ortholog of the mouse progressive ankylosis gene, result in craniometaphyseal dysplasia. <span><span class="ref-journal">Nat Genet. </span>2001;<span class="ref-vol">28</span>:37–41.</span> [<a href="/pubmed/11326272" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11326272</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="clcn7.REF.ott.2013.292">Ott C-E, Fischer B, Schr&#x000f6;ter P, Richter R, Gupta N, Verma N, Kabra M, Mundlos S, Rajab A, Neitzel H, Kornak U. Severe neuronopathic autosomal recessive osteopetrosis due to homozygous deletions affecting OSTM1. <span><span class="ref-journal">Bone. </span>2013;<span class="ref-vol">55</span>:292–7.</span> [<a href="/pubmed/23685543" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23685543</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="clcn7.REF.orchard.2015.270">Orchard PJ, Fasth AL, Le Rademacher J, He W, Boelens JJ, Horwitz EM, Al-Seraihy A, Ayas M, Bonfim CM, Boulad F, Lund T, Buchbinder DK, Kapoor N, O'Brien TA, Perez MA, Veys PA, Eapen M. Hematopoietic stem cell transplantation for infantile osteopetrosis. <span><span class="ref-journal">Blood. </span>2015;<span class="ref-vol">126</span>:270–6.</span> [<a href="/pmc/articles/PMC4497967/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4497967</span></a>] [<a href="/pubmed/26012570" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26012570</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="clcn7.REF.palagano.2015.1814">Palagano E, Blair HC, Pangrazio A, Tourkova I, Strina D, Angius A, Cuccuru G, Oppo M, Uva P, Van Hul W, Boudin E, Superti-Furga A, Faletra F, Nocerino A, Ferrari MC, Grappiolo G, Monari M, Montanelli A, Vezzoni P, Villa A, Sobacchi C. Buried in the Middle but Guilty: Intronic Mutations in the TCIRG1 Gene Cause Human Autosomal Recessive Osteopetrosis. <span><span class="ref-journal">J Bone Miner Res. </span>2015;<span class="ref-vol">30</span>:1814–21.</span> [<a href="/pubmed/25829125" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25829125</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="clcn7.REF.pangrazio.2013.1041">Pangrazio A, Fasth A, Sbardellati A, Orchard PJ, Kasow KA, Raza J, Albayrak C, Albayrak D, Vanakker OM, De Moerloose B, Vellodi A, Notarangelo LD, Schlack C, Strauss G, K&#x000fc;hl JS, Caldana E, Iacono NL, Susani L, Kornak U, Schulz A, Vezzoni P, Villa A, Sobacchi C. SNX10 mutations define a subgroup of human autosomal recessive osteopetrosis with variable clinical severity. <span><span class="ref-journal">J Bone Miner Res. </span>2013;<span class="ref-vol">28</span>:1041–9.</span> [<a href="/pubmed/23280965" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23280965</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="clcn7.REF.pangrazio.2012.250">Pangrazio A, Frattini A, Valli R, Maserati E, Susani L, Vezzoni P, Villa A, Al-Herz W, Sobacchi C. A homozygous contiguous gene deletion in chromosome 16p13.3 leads to autosomal recessive osteopetrosis in a Jordanian patient. <span><span class="ref-journal">Calcif Tissue Int. </span>2012;<span class="ref-vol">91</span>:250–4.</span> [<a href="/pubmed/22847576" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22847576</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="clcn7.REF.pangrazio.2006.1098">Pangrazio A, Poliani PL, Megarbane A, Lefranc G, Lanino E, Di Rocco M, Rucci F, Lucchini F, Ravanini M, Facchetti F, Abinun M, Vezzoni P, Villa A, Frattini A. Mutations in OSTM1 (grey lethal) define a particularly severe form of autosomal recessive osteopetrosis with neural involvement. <span><span class="ref-journal">J Bone Miner Res. </span>2006;<span class="ref-vol">21</span>:1098–105.</span> [<a href="/pubmed/16813530" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16813530</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="clcn7.REF.pangrazio.2010.e1071">Pangrazio A, Pusch M, Caldana E, Frattini A, Lanino E, Tamhankar PM, Phadke S, Lopez AG, Orchard P, Mihci E, Abinun M, Wright M, Vettenranta K, Bariae I, Melis D, Tezcan I, Baumann C, Locatelli F, Zecca M, Horwitz E, Mansour LS, Van Roij M, Vezzoni P, Villa A, Sobacchi C. Molecular and clinical heterogeneity in CLCN7-dependent osteopetrosis: report of 20 novel mutations. <span><span class="ref-journal">Hum Mutat. </span>2010;<span class="ref-vol">31</span>:E1071–80.</span> [<a href="/pubmed/19953639" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19953639</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="clcn7.REF.pangrazio.2014.122">Pangrazio A, Puddu A, Oppo M, Valentini M, Zammataro L, Vellodi A, Gener B, Llano-Rivas I, Raza J, Atta I, Vezzoni P, Superti-Furga A, Villa A, Sobacchi C. Exome sequencing identifies CTSK mutations in patients originally diagnosed as intermediate osteopetrosis. <span><span class="ref-journal">Bone. </span>2014;<span class="ref-vol">59</span>:122–6.</span> [<a href="/pmc/articles/PMC3885796/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3885796</span></a>] [<a href="/pubmed/24269275" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24269275</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="clcn7.REF.schulz.2010.e12585">Schulz P, Werner J, Stauber T, Henriksen K, Fendler K. The G215R mutation in the Cl-/H+-antiporter ClC-7 found in ADO II osteopetrosis does not abolish function but causes a severe trafficking defect. <span><span class="ref-journal">PLoS One. </span>2010;<span class="ref-vol">5</span>:e12585.</span> [<a href="/pmc/articles/PMC2935355/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2935355</span></a>] [<a href="/pubmed/20830208" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20830208</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="clcn7.REF.shroff.2012.1766">Shroff R, Beringer O, Rao K, Hofbauer L, Schulz A. Denosumab for post-transplantation hypercalcemia in osteopetrosis. <span><span class="ref-journal">N Engl J Med. </span>2012;<span class="ref-vol">367</span>:1766–7.</span> [<a href="/pubmed/23113501" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23113501</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="clcn7.REF.sobacchi.2001.1767">Sobacchi C, Frattini A, Orchard P, Porras O, Tezcan I, Andolina M, Babul-Hirji R, Baric I, Canham N, Chitayat D, Dupuis-Girod S, Ellis I, Etzioni A, Fasth A, Fisher A, Gerritsen B, Gulino V, Horwitz E, Klamroth V, Lanino E, Mirolo M, Musio A, Matthijs G, Nonomaya S, Notarangelo LD, Ochs HD, Superti Furga A, Valiaho J, van Hove JL, Vihinen M, Vujic D, Vezzoni P, Villa A. The mutational spectrum of human malignant autosomal recessive osteopetrosis. <span><span class="ref-journal">Hum Mol Genet. </span>2001;<span class="ref-vol">10</span>:1767–73.</span> [<a href="/pubmed/11532986" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11532986</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="clcn7.REF.sobacchi.2007.960">Sobacchi C, Frattini A, Guerrini MM, Abinun M, Pangrazio A, Susani L, Bredius R, Mancini G, Cant A, Bishop N, Grabowski P, Del Fattore A, Messina C, Errigo G, Coxon FP, Scott DI, Teti A, Rogers MJ, Vezzoni P, Villa A Helfrich MH. Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL. <span><span class="ref-journal">Nat Genet. </span>2007;<span class="ref-vol">39</span>:960–2.</span> [<a href="/pubmed/17632511" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17632511</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="clcn7.REF.sobacchi.2014.1646">Sobacchi C, Pangrazio A, Lopez AG, Gomez DP, Caldana ME, Susani L, Vezzoni P, Villa A. As little as needed: the extraordinary case of a mild recessive osteopetrosis owing to a novel splicing hypomorphic mutation in the TCIRG1 gene. <span><span class="ref-journal">J Bone Miner Res. </span>2014;<span class="ref-vol">29</span>:1646–50.</span> [<a href="/pmc/articles/PMC4258090/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4258090</span></a>] [<a href="/pubmed/24535816" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24535816</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="clcn7.REF.sobacchi.2013.522">Sobacchi C, Schulz A, Coxon FP, Helfrich MH. Osteopetrosis: genetics, treatment and new insights into osteoclast function. <span><span class="ref-journal">Nat Rev Endocrinol. </span>2013;<span class="ref-vol">9</span>:522–36.</span> [<a href="/pubmed/23877423" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23877423</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="clcn7.REF.souraty.2007.188">Souraty N, Noun P, Djambas-Khayat C, Chouery E, Pangrazio A, Villa A, Lefranc G, Frattini A, M&#x000e9;garban&#x000e9; A. Molecular study of six families originating from the Middle-East and presenting with autosomal recessive osteopetrosis. <span><span class="ref-journal">Eur J Med Genet. </span>2007;<span class="ref-vol">50</span>:188–99.</span> [<a href="/pubmed/17400532" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17400532</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="clcn7.REF.steward.2003.87">Steward CG. Neurological aspects of osteopetrosis. <span><span class="ref-journal">Neuropathol Appl Neurobiol. </span>2003;<span class="ref-vol">29</span>:87–97.</span> [<a href="/pubmed/12662317" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12662317</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="clcn7.REF.steward.2004.63">Steward CG, Pellier I, Mahajan A, Ashworth MT, Stuart AG, Fasth A, Lang D, Fischer A, Friedrich W, Schulz AS. Severe pulmonary hypertension: a frequent complication of stem cell transplantation for malignant infantile osteopetrosis. <span><span class="ref-journal">Br J Haematol. </span>2004;<span class="ref-vol">124</span>:63–71.</span> [<a href="/pubmed/14675409" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14675409</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="clcn7.REF.strickland.2005.815">Strickland JP, Berry DJ. Total joint arthroplasty in patients with osteopetrosis: a report of 5 cases and review of the literature. <span><span class="ref-journal">J Arthroplasty. </span>2005;<span class="ref-vol">20</span>:815–20.</span> [<a href="/pubmed/16139724" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16139724</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="clcn7.REF.teitelbaum.2003.638">Teitelbaum SL, Ross FP. Genetic regulation of osteoclast development and function. <span><span class="ref-journal">Nat Rev Genet. </span>2003;<span class="ref-vol">4</span>:638–49.</span> [<a href="/pubmed/12897775" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12897775</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="clcn7.REF.van_wesenbeeck.2003.763">Van Wesenbeeck L, Cleiren E, Gram J, Beals RK, B&#x000e9;nichou O, Scopelliti D, Key L, Renton T, Bartels C, Gong Y, Warman ML, De Vernejoul MC, Bollerslev J, Van Hul W. Six novel missense mutations in the LDL receptor-related protein 5 (LRP5) gene in different conditions with an increased bone density. <span><span class="ref-journal">Am J Hum Genet. </span>2003;<span class="ref-vol">72</span>:763–71.</span> [<a href="/pmc/articles/PMC1180253/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1180253</span></a>] [<a href="/pubmed/12579474" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12579474</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="clcn7.REF.van_wesenbeeck.2007.919">Van Wesenbeeck L, Odgren PR, Coxon FP, Frattini A, Moens P, Perdu B, MacKay CA, Van Hul E, Timmermans JP, Vanhoenacker F, Jacobs R, Peruzzi B, Teti A, Helfrich MH, Rogers MJ, Villa A, Van Hul W. Involvement of PLEKHM1 in osteoclastic vesicular transport and osteopetrosis in incisors absent rats and humans. <span><span class="ref-journal">J Clin Invest. </span>2007;<span class="ref-vol">117</span>:919–30.</span> [<a href="/pmc/articles/PMC1838941/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1838941</span></a>] [<a href="/pubmed/17404618" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17404618</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="clcn7.REF.vanhoenacker.2000.1423">Vanhoenacker FM, De Beuckeleer LH, Van Hul W, Balemans W, Tan GJ, Hill SC, De Schepper AM. Sclerosing bone dysplasias: genetic and radioclinical features. <span><span class="ref-journal">Eur Radiol. </span>2000;<span class="ref-vol">10</span>:1423–33.</span> [<a href="/pubmed/10997431" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10997431</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="clcn7.REF.waguespack.2003.1513">Waguespack SG, Koller DL, White KE, Fishburn T, Carn G, Buckwalter KA, Johnson M, Kocisko M, Evans WE, Foroud T, Econs MJ. Chloride channel 7 (ClCN7) gene mutations and autosomal dominant osteopetrosis, type II. <span><span class="ref-journal">J Bone Miner Res. </span>2003;<span class="ref-vol">18</span>:1513–8.</span> [<a href="/pubmed/12929941" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12929941</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="clcn7.REF.wilson.2000.449">Wilson CJ, Vellodi A. Autosomal recessive osteopetrosis: diagnosis, management, and outcome. <span><span class="ref-journal">Arch Dis Child. </span>2000;<span class="ref-vol">83</span>:449–52.</span> [<a href="/pmc/articles/PMC1718540/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1718540</span></a>] [<a href="/pubmed/11040159" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11040159</span></a>]</div></li></ul></div></div><div id="clcn7.Chapter_Notes"><h2 id="_clcn7_Chapter_Notes_">Chapter Notes</h2><div id="clcn7.Author_Information"><h3>Author Information</h3><p>Guidelines for diagnosis, therapy, and follow up for this disorder are available <a href="https://esid.org/content/download/15294/420706/file/00_OP_Guidelines_V3.pdf" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a> (pdf) and from author Ansgar Schulz, MD at ansgar.schulz@uniklinik-ulm.de.</p></div><div id="clcn7.Author_History"><h3>Author History</h3><p>Marie-Christine de Vernejoul, MD, PhD; H&#x000f4;pital Lariboisi&#x000e8;re (2007-2016)<br />Uwe Kornak, MD, PhD (2007-present)<br />Ansgar Schulz, MD (2007-present)<br />Cristina Sobacchi, MS (2016-present)<br />Anna Villa, MD, PhD (2016-present)</p></div><div id="clcn7.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>9 June 2016 (ha) Comprehensive update posted live</div></li><li class="half_rhythm"><div>20 June 2013 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>14 October 2010 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>12 February 2007 (me) Review posted live</div></li><li class="half_rhythm"><div>8 September 2006 (uk) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK1127</span><span class="label">PMID: <a href="/pubmed/20301306" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">20301306</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/cc2-leuk/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/clpb-def/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK1127&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK1127/?report=reader">PubReader</a></li><li><a href="/books/NBK1127/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK1127" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK1127" style="display:none" title="Cite this Page"><div class="bk_tt">Sobacchi C, Villa A, Schulz A, et al. CLCN7-Related Osteopetrosis. 2007 Feb 12 [Updated 2016 Jun 9]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK1127/pdf/Bookshelf_NBK1127.pdf">PDF version of this page</a> (560K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#clcn7.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#clcn7.GeneReview_Scope" ref="log$=inpage&amp;link_id=inpage"><i>GeneReview</i> Scope</a></li><li><a href="#clcn7.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#clcn7.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#clcn7.Genetically_Related_Allelic_Disord" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#clcn7.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#clcn7.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#clcn7.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#clcn7.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#clcn7.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#clcn7.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#clcn7.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=1186[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">CLCN7</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Variations in ClinVar</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=NBK1127+AND+genereviews[submitter]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Variations from this GeneReview in ClinVar</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=1465940" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=1465940" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=1465940" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=1465940" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301575" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Fanconi Anemia</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Fanconi Anemia<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Mehta PA, Tolar J. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/28975865" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Novel mutations of CLCN7 cause autosomal dominant osteopetrosis type II (ADOII) and intermediate autosomal recessive osteopetrosis (ARO) in seven Chinese families.</a><span class="source">[Postgrad Med. 2017]</span><div class="brieflinkpop offscreen_noflow">Novel mutations of CLCN7 cause autosomal dominant osteopetrosis type II (ADOII) and intermediate autosomal recessive osteopetrosis (ARO) in seven Chinese families.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Zhang X, Wei Z, He J, Wang C, Zhang Z. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Postgrad Med. 2017 Nov; 129(8):934-942. Epub 2017 Oct 11.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301472" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">COL1A1/2</i> Osteogenesis Imperfecta</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">COL1A1/2</i> Osteogenesis Imperfecta<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Steiner RD, Basel D. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301541" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Genetic Atypical Hemolytic-Uremic Syndrome</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Genetic Atypical Hemolytic-Uremic Syndrome<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Noris M, Bresin E, Mele C, Remuzzi G. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/22419446" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Long-term survival in infantile malignant autosomal recessive osteopetrosis secondary to homozygous p.Arg526Gln mutation in CLCN7.</a><span class="source">[Am J Med Genet A. 2012]</span><div class="brieflinkpop offscreen_noflow">Long-term survival in infantile malignant autosomal recessive osteopetrosis secondary to homozygous p.Arg526Gln mutation in CLCN7.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Kantaputra PN, Thawanaphong S, Issarangporn W, Klangsinsirikul P, Ohazama A, Sharpe P, Supanchart C. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Am J Med Genet A. 2012 Apr; 158A(4):909-16. Epub 2012 Mar 14.</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=20301306" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=20301306" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e04128fdde0891169ae2f47">CLCN7-Related Osteopetrosis - GeneReviews®</a><div class="ralinkpop offscreen_noflow">CLCN7-Related Osteopetrosis - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T20:53:19-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal103&amp;ncbi_phid=CE8A8CC6E040B4A1000000000314011D&amp;ncbi_session=CE8A8CC6E04128E1_0788SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK1127%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK1127&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK1127/&amp;ncbi_pagename=CLCN7-Related Osteopetrosis - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8A8CC6E04128E1_0788SID /projects/books/PBooks@5.22 portal103 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>